You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethotrexate
Accession NumberDB00563  (APRD00353)
TypeSmall Molecule
GroupsApproved
DescriptionAn antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of tetrahydrofolate dehydrogenase and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. [PubChem]
Structure
Thumb
Synonyms
4-amino-10-methylfolic acid
4-amino-N(10)-Methylpteroylglutamic acid
Amethopterin
Emtexate
Ledertrexate
Methotrexat
Méthotrexate
Methotrexatum
Metotrexato
MTX
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Rheumatrex
Trexall
External IDs Not Available
Product Ingredients
IngredientUNIICASInChI KeyDetails
Methotrexate Sodium3IG1E710ZN 7413-34-5DASQOOZCTWOQPA-GXKRWWSZSA-LDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Jamp-methotrexateSolution25 mgIntra-arterial; Intramuscular; Intrathecal; IntravenousJamp Pharma Corporation2014-03-12Not applicableCanada
MethotrexateTablet2.5 mg/1OralRebel Distributors1953-12-07Not applicableUs
MethotrexateTablet2.5 mg/1OralDispensing Solutions, Inc.1953-12-07Not applicableUs
MethotrexateTablet2.5 mg/1OralRemedy Repack2015-09-232017-01-26Us
MethotrexateTablet2.5 mg/1OralRemedy Repack2017-02-15Not applicableUs
MethotrexateTablet2.5 mg/1OralPd Rx Pharmaceuticals, Inc.1953-12-07Not applicableUs
MethotrexateTablet2.5 mg/1OralDAVA Pharmaceuticals, Inc.1953-12-07Not applicableUs
MethotrexateTablet2.5 mg/1OralA S Medication Solutions1953-12-07Not applicableUs
MethotrexateSolution25 mgIntra-arterial; Intramuscular; IntravenousPfizer1997-01-242011-05-03Canada
MethotrexateInjection, solution25 mg/mLIntra-arterial; Intramuscular; IntravenousHospira Worldwide, Inc.1959-08-10Not applicableUs
MethotrexateTablet2.5 mg/1OralA S Medication Solutions1953-12-07Not applicableUs
MethotrexateTablet2.5 mg/1OralMajor2009-06-01Not applicableUs
MethotrexateInjection, solution25 mg/mLIntra-arterial; Intramuscular; Intrathecal; IntravenousHospira Worldwide, Inc.1959-08-10Not applicableUs
MethotrexateTablet2.5 mgOralPfizer1996-11-15Not applicableCanada
Methotrexate Dbl Inj 10mg/mlLiquid10 mgIntravenousDavid Bull Laboratories (Pty) Ltd.1985-12-311997-08-14Canada
Methotrexate Dbl Inj 2.5mg/mlLiquid2.5 mgIntravenousDavid Bull Laboratories (Pty) Ltd.1985-12-311998-08-13Canada
Methotrexate Dbl Inj 25mg/mlLiquid25 mgIntravenousDavid Bull Laboratories (Pty) Ltd.1985-12-311998-08-13Canada
Methotrexate Injection BPSolution25 mgIntra-arterial; Intramuscular; Intrathecal; IntravenousUman PharmaNot applicableNot applicableCanada
Methotrexate Injection USPSolution25 mgIntra-arterial; Intramuscular; Intrathecal; Intravenous; IntraventricularHospira, Inc.1998-07-13Not applicableCanada
Methotrexate Injection USPSolution25 mgIntravenousHospira, Inc.1997-07-30Not applicableCanada
Methotrexate Injection USPSolution25 mgIntra-arterial; Intramuscular; IntravenousSandoz Canada Incorporated2013-02-14Not applicableCanada
Methotrexate Injection USPSolution25 mgIntra-arterial; Intramuscular; IntravenousHospira, Inc.1998-04-30Not applicableCanada
Methotrexate Injection USPSolution10 mgIntra-arterial; Intramuscular; Intrathecal; Intravenous; IntraventricularHospira, Inc.1997-07-30Not applicableCanada
Methotrexate Injection, BPSolution7.5 mgIntra-arterial; Intramuscular; Intrathecal; IntravenousPharmascience Inc2014-05-08Not applicableCanada
Methotrexate Injection, BPSolution25 mgIntra-arterial; Intramuscular; Intrathecal; IntravenousAccord Healthcare Limited2011-09-30Not applicableCanada
Methotrexate Injection, BPSolution10 mgIntra-arterial; Intramuscular; Intrathecal; IntravenousPharmascience Inc2014-05-08Not applicableCanada
Methotrexate Injection, BPSolution15 mgIntra-arterial; Intramuscular; Intrathecal; IntravenousPharmascience Inc2014-05-08Not applicableCanada
Methotrexate Injection, BPSolution20 mgIntra-arterial; Intramuscular; Intrathecal; IntravenousPharmascience Inc2014-05-08Not applicableCanada
Methotrexate Injection, BPSolution25 mgIntra-arterial; Intramuscular; Intrathecal; IntravenousPharmascience Inc2014-05-08Not applicableCanada
Methotrexate Injection, USPSolution25 mgIntra-arterial; Intramuscular; Intrathecal; IntravenousMylan Pharmaceuticals2014-08-14Not applicableCanada
Methotrexate PF/sa InjectionSolution25 mgIntra-arterial; Intramuscular; Intrathecal; IntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Methotrexate Sod Inj 25mg/ml USPLiquid25 mgIntra-arterial; Intramuscular; Intrathecal; IntravenousDavid Bull Laboratories (Pty) Ltd.1990-12-311998-08-13Canada
Methotrexate SodiumTablet2.5 mg/1OralGen Pak Solutions, Llc2012-10-01Not applicableUs
Methotrexate Sodium Inj 20mgPowder, for solution20 mgIntramuscular; Intrathecal; IntravenousLederle Cyanamid Canada Inc.1977-12-311997-08-14Canada
Methotrexate Sodium Inj 25.0mg/mlLiquid25 mgIntramuscular; Intrathecal; IntravenousLederle Cyanamid Canada Inc.1976-12-311997-08-14Canada
Methotrexate Sodium Inj 25mg/mlLiquid50 mgIntramuscular; Intrathecal; IntravenousLederle Cyanamid Canada Inc.1981-12-311997-08-14Canada
Methotrexate Sodium Inj 25mg/ml USPLiquid25 mgIntra-arterial; Intramuscular; Intrathecal; IntravenousDavid Bull Laboratories (Pty) Ltd.1992-12-311999-08-10Canada
Methotrexate Sodium InjectionSolution25 mgIntra-arterial; Intramuscular; Intrathecal; IntravenousTeva1995-12-31Not applicableCanada
Methotrexate Sodium Injection USPSolution25 mgIntra-arterial; Intramuscular; Intrathecal; Intravenous; IntraventricularPfizer1996-09-052006-08-02Canada
Methotrexate Tab 2.5mgTablet2.5 mgOralLederle Cyanamid Canada Inc.1955-12-311997-08-14Canada
Methotrexate Tab 2.5mg USPTablet2.5 mgOralDavid Bull Laboratories (Pty) Ltd.1991-12-312000-08-01Canada
Methotrexate Tablets, USPTablet10 mgOralHospira, Inc.2004-04-12Not applicableCanada
Methotrexate-liq Im IV Iar Int Ivr 25mg/mlLiquid25 mgIntra-arterial; Intramuscular; Intrathecal; IntravenousWyeth Ayerst Canada Inc.1997-02-042001-09-19Canada
Methotrexate-pws Im IV Iar Int Ivr 20mg/vialPowder, for solution20 mgIntra-arterial; Intramuscular; Intrathecal; IntravenousWyeth Ayerst Canada Inc.1997-02-042001-05-22Canada
MetojectSolution20 mgIntra-arterial; Intramuscular; IntravenousMedexus Inc2008-05-30Not applicableCanada
MetojectSolution7.5 mgIntra-arterial; Intramuscular; IntravenousMedexus Inc2009-01-26Not applicableCanada
MetojectSolution10 mgIntra-arterial; Intramuscular; IntravenousMedexus Inc2009-01-26Not applicableCanada
MetojectSolution15 mgIntra-arterial; Intramuscular; IntravenousMedexus Inc2009-01-26Not applicableCanada
MetojectSolution25 mgIntra-arterial; Intramuscular; IntravenousMedexus Inc2009-01-26Not applicableCanada
Metoject SubcutaneousSolution12.5 mgSubcutaneousMedexus IncNot applicableNot applicableCanada
Metoject SubcutaneousSolution17.5 mgSubcutaneousMedexus Inc2016-12-02Not applicableCanada
Metoject SubcutaneousSolution7.5 mgSubcutaneousMedexus IncNot applicableNot applicableCanada
Metoject SubcutaneousSolution22.5 mgSubcutaneousMedexus Inc2016-12-02Not applicableCanada
Metoject SubcutaneousSolution10 mgSubcutaneousMedexus IncNot applicableNot applicableCanada
Metoject SubcutaneousSolution20 mgSubcutaneousMedexus Inc2016-12-02Not applicableCanada
Metoject SubcutaneousSolution15 mgSubcutaneousMedexus IncNot applicableNot applicableCanada
Metoject SubcutaneousSolution25 mgSubcutaneousMedexus Inc2016-12-02Not applicableCanada
NordimetInjection, solution10 mgSubcutaneousNordic Group Bv2016-08-18Not applicableEu
NordimetInjection, solution12.5 mgSubcutaneousNordic Group Bv2016-08-18Not applicableEu
NordimetInjection, solution15 mgSubcutaneousNordic Group Bv2016-08-18Not applicableEu
NordimetInjection, solution25 mgSubcutaneousNordic Group Bv2016-08-18Not applicableEu
NordimetInjection, solution17.5 mgSubcutaneousNordic Group Bv2016-08-18Not applicableEu
NordimetInjection, solution20 mgSubcutaneousNordic Group Bv2016-08-18Not applicableEu
NordimetInjection, solution7.5 mgSubcutaneousNordic Group Bv2016-08-18Not applicableEu
NordimetInjection, solution22.5 mgSubcutaneousNordic Group Bv2016-08-18Not applicableEu
OtrexupInjection, solution15 mg/.4mLSubcutaneousAntares Pharma, Inc.2013-10-11Not applicableUs
OtrexupInjection, solution22.5 mg/.4mLSubcutaneousAntares Pharma, Inc.2013-10-11Not applicableUs
OtrexupInjection, solution20 mg/.4mLSubcutaneousAntares Pharma, Inc.2013-10-11Not applicableUs
OtrexupInjection, solution25 mg/.4mLSubcutaneousAntares Pharma, Inc.2013-10-11Not applicableUs
OtrexupInjection, solution7.5 mg/.4mLSubcutaneousAntares Pharma, Inc.2013-10-11Not applicableUs
OtrexupInjection, solution12.5 mg/.4mLSubcutaneousAntares Pharma, Inc.2013-10-11Not applicableUs
OtrexupInjection, solution10 mg/.4mLSubcutaneousAntares Pharma, Inc.2013-10-11Not applicableUs
OtrexupInjection, solution17.5 mg/.4mLSubcutaneousAntares Pharma, Inc.2013-10-11Not applicableUs
RasuvoInjection, solution17.5 mg/.35mLSubcutaneousMedac Pharma, Inc2014-07-10Not applicableUs
RasuvoInjection, solution20 mg/.4mLSubcutaneousMedac Pharma, Inc2014-07-10Not applicableUs
RasuvoInjection, solution7.5 mg/.15mLSubcutaneousMedac Pharma, Inc2014-07-10Not applicableUs
RasuvoInjection, solution22.5 mg/.45mLSubcutaneousMedac Pharma, Inc2014-07-10Not applicableUs
RasuvoInjection, solution10 mg/.2mLSubcutaneousMedac Pharma, Inc2014-07-10Not applicableUs
RasuvoInjection, solution25 mg/.5mLSubcutaneousMedac Pharma, Inc2014-07-10Not applicableUs
RasuvoInjection, solution30 mg/.6mLSubcutaneousMedac Pharma, Inc2014-07-10Not applicableUs
RasuvoInjection, solution12.5 mg/.25mLSubcutaneousMedac Pharma, Inc2014-07-10Not applicableUs
RasuvoInjection, solution27.5 mg/.55mLSubcutaneousMedac Pharma, Inc2014-07-10Not applicableUs
RasuvoInjection, solution15 mg/.3mLSubcutaneousMedac Pharma, Inc2014-07-10Not applicableUs
Ratio-methotrexate SodiumTablet2.5 mgOralTeva2001-11-14Not applicableCanada
Rheumatrex Dose PackTablet2.5 mg/1OralDAVA Pharmaceuticals, Inc.1953-07-12Not applicableUs
Rheumatrex Tab 2.5mgTablet2.5 mgOralLederle Cyanamid Canada Inc.1990-12-312000-08-02Canada
Rheumatrex-tab 2.5mgTablet2.5 mgOralWyeth Ayerst Canada Inc.1999-04-122000-08-02Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-methotrexateTablet2.5 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-methotrexateTablet2.5 mgOralHospira, Inc.1999-09-17Not applicableCanada
MethotrexateTablet2.5 mg/1OralA S Medication Solutions1990-11-01Not applicableUs
MethotrexateTablet2.5 mg/1OralCadila Pharnmaceuticals2017-02-09Not applicableUs
MethotrexateInjection25 mg/mLIntra-arterial; Intramuscular; Intrathecal; IntravenousPfizer Laboratories Div Pfizer Inc.2012-03-30Not applicableUs
MethotrexateInjection, solution1 g/40mLIntra-arterial; Intramuscular; Intrathecal; IntravenousMylan Institutional2012-06-27Not applicableUs
MethotrexateTablet2.5 mg/1OralRebel Distributors1990-10-15Not applicableUs
MethotrexateInjection, solution25 mg/mLIntra-arterial; Intramuscular; Intrathecal; IntravenousTeva Parenteral Medicines, Inc.2012-08-01Not applicableUs
MethotrexateTablet2.5 mg/1OralMylan Institutional1995-07-13Not applicableUs
MethotrexateInjection, solution25 mg/mLIntra-arterial; Intramuscular; Intrathecal; IntravenousPhysicians Total Care, Inc.2003-03-26Not applicableUs
MethotrexateInjection25 mg/mLIntra-arterial; Intramuscular; Intrathecal; IntravenousPfizer Laboratories Div Pfizer Inc.2012-03-30Not applicableUs
MethotrexateTablet2.5 mg/1OralAv Kare, Inc.2014-11-20Not applicableUs
MethotrexateInjection, solution25 mg/mLIntra-arterial; Intramuscular; Intrathecal; IntravenousTeva Parenteral Medicines, Inc.2012-08-01Not applicableUs
MethotrexateInjection, solution25 mg/mLIntra-arterial; Intramuscular; Intrathecal; IntravenousFresenius Kabi2003-04-03Not applicableUs
MethotrexateInjection25 mg/mLIntra-arterial; Intramuscular; Intrathecal; IntravenousMylan Institutional2012-03-30Not applicableUs
MethotrexateTablet2.5 mg/1OralPd Rx Pharmaceuticals, Inc.1990-11-01Not applicableUs
MethotrexateInjection, powder, lyophilized, for solution1 g/1Intra-arterial; Intramuscular; Intrathecal; IntravenousFresenius Kabi2000-01-22Not applicableUs
MethotrexateInjection25 mg/mLIntra-arterial; Intramuscular; Intrathecal; IntravenousPfizer Laboratories Div Pfizer Inc.2012-03-30Not applicableUs
MethotrexateTablet2.5 mg/1OralBarr Laboratories1990-11-01Not applicableUs
MethotrexateInjection25 mg/mLIntra-arterial; Intramuscular; Intrathecal; IntravenousMylan Institutional2012-03-30Not applicableUs
MethotrexateInjection25 mg/mLIntra-arterial; Intramuscular; Intrathecal; IntravenousMylan Institutional2012-03-30Not applicableUs
MethotrexateInjection, solution25 mg/mLIntra-arterial; Intramuscular; IntravenousFresenius Kabi2001-09-10Not applicableUs
MethotrexateInjection25 mg/mLIntra-arterial; Intramuscular; Intrathecal; IntravenousPfizer Laboratories Div Pfizer Inc.2012-03-30Not applicableUs
MethotrexateInjection, solution25 mg/mLIntra-arterial; Intramuscular; Intrathecal; IntravenousTeva Parenteral Medicines, Inc.2012-08-012016-01-22Us
MethotrexateInjection25 mg/mLIntra-arterial; Intramuscular; Intrathecal; IntravenousMylan Institutional2012-03-30Not applicableUs
MethotrexateInjection25 mg/mLIntra-arterial; Intramuscular; Intrathecal; IntravenousMylan Institutional2012-03-30Not applicableUs
MethotrexateTablet2.5 mg/1OralMylan Pharmaceuticals1992-05-18Not applicableUs
MethotrexateTablet2.5 mg/1OralZydus Pharmaceuticals Usa, Inc.2017-02-09Not applicableUs
MethotrexateInjection25 mg/mLIntra-arterial; Intramuscular; Intrathecal; IntravenousPfizer Laboratories Div Pfizer Inc.2012-03-30Not applicableUs
MethotrexateInjection25 mg/mLIntra-arterial; Intramuscular; Intrathecal; IntravenousAccord Healthcare Limited2014-02-01Not applicableUs
MethotrexateInjection, solution25 mg/mLIntra-arterial; Intramuscular; Intrathecal; IntravenousTeva Parenteral Medicines, Inc.2012-07-31Not applicableUs
Methotrexate SodiumTablet2.5 mg/1OralRemedy Repack2011-07-212017-04-14Us
Methotrexate SodiumInjection, solution25 mg/mLIntra-arterial; Intramuscular; Intrathecal; IntravenousMylan Institutional2012-03-30Not applicableUs
Methotrexate SodiumTablet2.5 mg/1OralPhysicians Total Care, Inc.2007-12-05Not applicableUs
Methotrexate SodiumInjection, solution25 mg/mLIntra-arterial; Intramuscular; Intrathecal; IntravenousPfizer Laboratories Div Pfizer Inc.2012-03-30Not applicableUs
Methotrexate SodiumTablet2.5 mg/1OralWest Ward Pharmaceutical1994-08-01Not applicableUs
Methotrexate SodiumTablet2.5 mg/1Oralbryant ranch prepack1994-08-01Not applicableUs
Methotrexate SodiumTablet2.5 mg/1OralWest Ward Pharmaceutical1994-08-01Not applicableUs
Methotrexate SodiumInjection, solution25 mg/mLIntra-arterial; Intramuscular; Intrathecal; IntravenousSandoz2009-06-01Not applicableUs
Methotrexate SodiumTablet2.5 mg/1OralRemedy Repack2011-06-202017-04-14Us
Methotrexate SodiumInjection, solution25 mg/mLIntra-arterial; Intramuscular; Intrathecal; IntravenousSandoz2009-06-01Not applicableUs
TrexallTablet, film coated5 mg/1OralTeva Women's Health2001-05-03Not applicableUs
TrexallTablet, film coated7.5 mg/1OralTeva Women's Health2001-05-03Not applicableUs
TrexallTablet, film coated10 mg/1OralTeva Women's Health2001-05-03Not applicableUs
TrexallTablet, film coated15 mg/1OralTeva Women's Health2001-05-03Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AbitrexateTeva
AlltrexNaprod
ArtraitTRB
AtrexelSchering-Plough
BendatrexatBendalis
CarditrexCadila
DermotrexEast West
EbetrexEbewe
EmtexateNot Available
LedertrexateBiodim
MaxtrexPfizer
MeisushengHospira
MexateCadila HC
RheumatrexWyeth KK
TrexanAtafarm
ZexateDabur Pharma
Brand mixturesNot Available
Categories
UNIIYL5FZ2Y5U1
CAS number59-05-2
WeightAverage: 454.4393
Monoisotopic: 454.171315854
Chemical FormulaC20H22N8O5
InChI KeyFBOZXECLQNJBKD-ZDUSSCGKSA-N
InChI
InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1
IUPAC Name
(2S)-2-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)formamido]pentanedioic acid
SMILES
CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Pharmacology
IndicationMethotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is also indicated in the treatment of meningeal leukemia. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis. Methotrexate is indicated in the management of selected adults with severe, active rheumatoid arthritis (ACR criteria), or children with active polyarticular-course juvenile rheumatoid arthritis.
Structured Indications
PharmacodynamicsMethotrexate is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Methotrexate inhibits folic acid reductase which is responsible for the conversion of folic acid to tetrahydrofolic acid. At two stages in the biosynthesis of purines and at one stage in the synthesis of pyrimidines, one-carbon transfer reactions occur which require specific coenzymes synthesized in the cell from tetrahydrofolic acid. Tetrahydrofolic acid itself is synthesized in the cell from folic acid with the help of an enzyme, folic acid reductase. Methotrexate looks a lot like folic acid to the enzyme, so it binds to it quite strongly and inhibits the enzyme. Thus, DNA synthesis cannot proceed because the coenzymes needed for one-carbon transfer reactions are not produced from tetrahydrofolic acid because there is no tetrahydrofolic acid. Methotrexate selectively affects the most rapidly dividing cells (neoplastic and psoriatic cells). Methotrexate is also indicated in the management of severe, active, classical, or definite rheumatoid arthritis.
Mechanism of actionMethotrexate anti-tumor activity is a result of the inhibition of folic acid reductase, leading to inhibition of DNA synthesis and inhibition of cellular replication. The mechanism involved in its activity against rheumatoid arthritis is not known.
TargetKindPharmacological actionActionsOrganismUniProt ID
Dihydrofolate reductaseProteinyes
inhibitor
HumanP00374 details
Related Articles
AbsorptionOral absorption is dose dependent in adults and leukemic pediatric patients. In adults, peak serum levels are reached within one to two hours. At doses of 30 mg/m^2 or less, methotrexate is generally well absorbed with a mean bioavailability of 60%. At doses greater than 80 mg/m^2, the absorption of the doses is significantly less due to a saturation effect.
Volume of distribution
  • 0.18 L/kg [initial volume of distribution (Vd)]
  • 0.4 – 0.8 L/kg [steady state Vd]
    Methotrexate competes with reduced folates for active transport across cell membranes by means of a single carrier-mediated active transport process. At serum concentrations greater than 100 micromolar, passive diffusion becomes a major pathway by which effective intracellular concentrations can be achieved. Methotrexate does not cross the blood-brain-barrier.
Protein binding50% bound to protein, primarily to albumin
Metabolism

Methotrexate undergoes hepatic and intracellular metabolism to polyglutamated forms which can be converted back to methotrexate by hydroxylase enzymes. These polyglutamates act as inhibitors of dihydrofolate reductase and thymidylate synthetase. A small amount of metabolism to 7-hydroxymethotrexate may occur at doses commonly prescribed. Furthermore, intestinal flora partially metabolizes methotrexate after oral administration.

SubstrateEnzymesProduct
Methotrexate
7-hydroxymethotrexateDetails
Route of eliminationRenal excretion is the primary route of elimination and is dependent upon dosage and route of administration. IV administration, 80% to 90% of the administered dose is excreted unchanged in the urine within 24 hours. There is limited biliary excretion amounting to 10% or less of the administered dose.
Half lifeLow doses (less than 30 mg/m^2): 3 to 10 hours; High doses: 8 to 15 hours.
Clearance

Methotrexate clearance rates vary widely and are generally decreased at higher doses. Delayed drug clearance has been identified as one of the major factors responsible for methotrexate toxicity.

ToxicitySymptoms of overdose include bone marrow suppression and gastrointestinal toxicity. LD50=43mg/kg(orally in rat).
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Methotrexate Action PathwayDrug actionSMP00432
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeSNP RS IDsAllele nameGenotypeDefining ChangeType(s)DescriptionDetails
Canalicular multispecific organic anion transporter 1Not AvailableABCC2 IVS 23+56(C;C) or (C;T)T alleleADR Directly StudiedGeneral toxicity (gastrointestinal and hepatotoxicity) Details
Methylenetetrahydrofolate reductase---(T;T) or (C;T)T alleleADR Directly StudiedMucositis, hepatic toxicity, thrombocytopenia, alopecia Details
Interactions
Drug Interactions
DrugInteractionDrug group
AceclofenacThe serum concentration of Methotrexate can be increased when it is combined with Aceclofenac.Approved
AcetaminophenThe serum concentration of Methotrexate can be increased when it is combined with Acetaminophen.Approved
AcetovanilloneThe serum concentration of Methotrexate can be increased when it is combined with Acetovanillone.Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Methotrexate.Approved
Acetylsalicylic acidThe serum concentration of Methotrexate can be increased when it is combined with Acetylsalicylic acid.Approved, Vet Approved
AcitretinAcitretin may increase the hepatotoxic activities of Methotrexate.Approved
AdapaleneThe serum concentration of Methotrexate can be increased when it is combined with Adapalene.Approved
AfatinibThe serum concentration of Methotrexate can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Methotrexate can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Methotrexate can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Methotrexate can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Methotrexate can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinAlitretinoin may increase the hepatotoxic activities of Methotrexate.Approved, Investigational
AmantadineThe serum concentration of Methotrexate can be increased when it is combined with Amantadine.Approved
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be increased when it is combined with Methotrexate.Experimental
AmdinocillinThe serum concentration of Methotrexate can be increased when it is combined with Amdinocillin.Withdrawn
Aminohippuric acidThe serum concentration of Methotrexate can be increased when it is combined with Aminohippuric acid.Approved
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Methotrexate.Approved
Aminosalicylic AcidThe serum concentration of Methotrexate can be increased when it is combined with Aminosalicylic Acid.Approved
AmiodaroneThe serum concentration of Methotrexate can be decreased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Methotrexate can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Methotrexate can be increased when it is combined with Amlodipine.Approved
AmoxicillinThe serum concentration of Methotrexate can be increased when it is combined with Amoxicillin.Approved, Vet Approved
AmpicillinThe serum concentration of Methotrexate can be increased when it is combined with Ampicillin.Approved, Vet Approved
AmprenavirThe serum concentration of Methotrexate can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Methotrexate can be increased when it is combined with Amsacrine.Approved
AnisodamineThe serum concentration of Methotrexate can be increased when it is combined with Anisodamine.Investigational
AntipyrineThe serum concentration of Methotrexate can be increased when it is combined with Antipyrine.Approved
ApremilastThe serum concentration of Methotrexate can be increased when it is combined with Apremilast.Approved, Investigational
AstemizoleThe serum concentration of Methotrexate can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Methotrexate can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Methotrexate can be increased when it is combined with Atenolol.Approved
AtorvastatinThe serum concentration of Methotrexate can be increased when it is combined with Atorvastatin.Approved
AzapropazoneThe serum concentration of Methotrexate can be increased when it is combined with Azapropazone.Withdrawn
AzelastineThe serum concentration of Methotrexate can be increased when it is combined with Azelastine.Approved
AzidocillinThe serum concentration of Methotrexate can be increased when it is combined with Azidocillin.Approved
AzithromycinThe serum concentration of Methotrexate can be increased when it is combined with Azithromycin.Approved
AzlocillinThe serum concentration of Methotrexate can be increased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Methotrexate can be increased when it is combined with Bacampicillin.Approved
BalsalazideThe serum concentration of Methotrexate can be increased when it is combined with Balsalazide.Approved, Investigational
BCGThe therapeutic efficacy of Bcg can be decreased when used in combination with Methotrexate.Investigational
BenoxaprofenThe serum concentration of Methotrexate can be increased when it is combined with Benoxaprofen.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Methotrexate can be increased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzocaineThe serum concentration of Methotrexate can be increased when it is combined with Benzocaine.Approved
BenzylpenicillinThe serum concentration of Methotrexate can be increased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicillin PotassiumThe serum concentration of Methotrexate can be increased when it is combined with Benzylpenicillin Potassium.Approved
Benzylpenicilloyl PolylysineThe serum concentration of Methotrexate can be increased when it is combined with Benzylpenicilloyl Polylysine.Approved
BepridilThe serum concentration of Methotrexate can be increased when it is combined with Bepridil.Approved, Withdrawn
Betulinic AcidThe serum concentration of Methotrexate can be increased when it is combined with Betulinic Acid.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Methotrexate.Approved, Investigational
BiperidenThe serum concentration of Methotrexate can be increased when it is combined with Biperiden.Approved
BosutinibThe serum concentration of Methotrexate can be increased when it is combined with Bosutinib.Approved
BromfenacThe serum concentration of Methotrexate can be increased when it is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Methotrexate can be increased when it is combined with Bromocriptine.Approved, Investigational
BucillamineThe serum concentration of Methotrexate can be increased when it is combined with Bucillamine.Investigational
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Methotrexate.Approved
BuprenorphineThe serum concentration of Methotrexate can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Methotrexate can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Methotrexate.Approved
CaffeineThe serum concentration of Methotrexate can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Methotrexate can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Methotrexate can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Methotrexate can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Methotrexate can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbenicillinThe serum concentration of Methotrexate can be increased when it is combined with Carbenicillin.Approved
CarindacillinThe serum concentration of Methotrexate can be increased when it is combined with Carindacillin.Approved
CarprofenThe serum concentration of Methotrexate can be increased when it is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Methotrexate can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Methotrexate can be increased when it is combined with Caspofungin.Approved
CastanospermineThe serum concentration of Methotrexate can be increased when it is combined with Castanospermine.Experimental
CelecoxibThe serum concentration of Methotrexate can be increased when it is combined with Celecoxib.Approved, Investigational
ChloroquineThe serum concentration of Methotrexate can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Methotrexate can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Methotrexate can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Methotrexate can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Methotrexate can be increased when it is combined with Cholesterol.Experimental
CholestyramineCholestyramine can cause a decrease in the absorption of Methotrexate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cholic AcidThe serum concentration of Methotrexate can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Methotrexate can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Methotrexate can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Methotrexate can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Methotrexate can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Methotrexate can be increased when it is combined with Clarithromycin.Approved
ClofazimineThe serum concentration of Methotrexate can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Methotrexate can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonixinThe serum concentration of Methotrexate can be increased when it is combined with Clonixin.Approved
ClotrimazoleThe serum concentration of Methotrexate can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
CloxacillinThe serum concentration of Methotrexate can be increased when it is combined with Cloxacillin.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Methotrexate is combined with Clozapine.Approved
CobicistatThe serum concentration of Methotrexate can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Methotrexate can be increased when it is combined with Colchicine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Methotrexate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Methotrexate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColforsinThe serum concentration of Methotrexate can be increased when it is combined with Colforsin.Experimental
CrizotinibThe serum concentration of Methotrexate can be increased when it is combined with Crizotinib.Approved
CurcuminThe serum concentration of Methotrexate can be increased when it is combined with Curcumin.Investigational
CyclacillinThe serum concentration of Methotrexate can be increased when it is combined with Cyclacillin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Methotrexate.Approved, Investigational
CyclosporineThe serum concentration of Methotrexate can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe serum concentration of Methotrexate can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe serum concentration of Methotrexate can be increased when it is combined with D-Limonene.Investigational
DaclatasvirThe serum concentration of Methotrexate can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Methotrexate can be increased when it is combined with Dactinomycin.Approved
DasatinibThe serum concentration of Methotrexate can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Methotrexate can be decreased when it is combined with Daunorubicin.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Methotrexate.Approved
dersalazineThe serum concentration of Methotrexate can be increased when it is combined with dersalazine.Investigational
DesipramineThe serum concentration of Methotrexate can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Methotrexate.Approved
DesloratadineThe serum concentration of Methotrexate can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Methotrexate can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexketoprofenThe serum concentration of Methotrexate can be increased when it is combined with Dexketoprofen.Approved
DextromethorphanThe serum concentration of Methotrexate can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Methotrexate can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicloxacillinThe serum concentration of Methotrexate can be increased when it is combined with Dicloxacillin.Approved, Vet Approved
DiflunisalThe serum concentration of Methotrexate can be increased when it is combined with Diflunisal.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Methotrexate.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Methotrexate.Approved
DihydroergotamineThe serum concentration of Methotrexate can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Methotrexate can be increased when it is combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Methotrexate can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Methotrexate.Approved, Investigational
DoxazosinThe serum concentration of Methotrexate can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Methotrexate can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Methotrexate can be decreased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Methotrexate can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Methotrexate can be increased when it is combined with Dronedarone.Approved
DroxicamThe serum concentration of Methotrexate can be increased when it is combined with Droxicam.Approved
DuvelisibThe serum concentration of Methotrexate can be increased when it is combined with Duvelisib.Investigational
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Methotrexate.Approved
E6201The serum concentration of Methotrexate can be increased when it is combined with E6201.Investigational
EbselenThe serum concentration of Methotrexate can be increased when it is combined with Ebselen.Investigational
ElbasvirThe serum concentration of Methotrexate can be increased when it is combined with Elbasvir.Approved
EltrombopagThe serum concentration of Methotrexate can be increased when it is combined with Eltrombopag.Approved
EnalaprilThe serum concentration of Methotrexate can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Methotrexate can be increased when it is combined with Enzalutamide.Approved
EpirizoleThe serum concentration of Methotrexate can be increased when it is combined with Epirizole.Approved
ErgonovineThe serum concentration of Methotrexate can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Methotrexate can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Methotrexate can be decreased when it is combined with Erythromycin.Approved, Vet Approved
EsomeprazoleThe serum concentration of Methotrexate can be increased when it is combined with Esomeprazole.Approved, Investigational
EstramustineThe serum concentration of Methotrexate can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Methotrexate can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Methotrexate can be decreased when it is combined with Estrone.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Methotrexate.Approved
EtanerceptThe serum concentration of Methotrexate can be increased when it is combined with Etanercept.Approved, Investigational
EtodolacThe serum concentration of Methotrexate can be increased when it is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe serum concentration of Methotrexate can be increased when it is combined with Etofenamate.Approved
EtoposideThe serum concentration of Methotrexate can be increased when it is combined with Etoposide.Approved
EtoricoxibThe serum concentration of Methotrexate can be increased when it is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Methotrexate can be increased when it is combined with Etravirine.Approved
Evening primrose oilThe serum concentration of Methotrexate can be increased when it is combined with Evening primrose oil.Approved
exisulindThe serum concentration of Methotrexate can be increased when it is combined with exisulind.Investigational
FelodipineThe serum concentration of Methotrexate can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenThe serum concentration of Methotrexate can be increased when it is combined with Fenbufen.Approved
FenoprofenThe serum concentration of Methotrexate can be increased when it is combined with Fenoprofen.Approved
FentanylThe serum concentration of Methotrexate can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Methotrexate can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Methotrexate can be increased when it is combined with Fidaxomicin.Approved
FingolimodMethotrexate may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FloctafenineThe serum concentration of Methotrexate can be increased when it is combined with Floctafenine.Approved, Withdrawn
FlucloxacillinThe serum concentration of Methotrexate can be increased when it is combined with Flucloxacillin.Approved
FluconazoleThe serum concentration of Methotrexate can be increased when it is combined with Fluconazole.Approved
FlunixinThe serum concentration of Methotrexate can be increased when it is combined with Flunixin.Vet Approved
FluoxetineThe serum concentration of Methotrexate can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Methotrexate can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Methotrexate can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Methotrexate can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenThe serum concentration of Methotrexate can be increased when it is combined with Flurbiprofen.Approved, Investigational
FluvoxamineThe serum concentration of Methotrexate can be increased when it is combined with Fluvoxamine.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Methotrexate.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be decreased when it is combined with Methotrexate.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Methotrexate.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Methotrexate is combined with G17DT.Investigational
GefitinibThe serum concentration of Methotrexate can be increased when it is combined with Gefitinib.Approved, Investigational
GenisteinThe serum concentration of Methotrexate can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Methotrexate is combined with GI-5005.Investigational
GlyburideThe serum concentration of Methotrexate can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Methotrexate can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Methotrexate can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Methotrexate can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Methotrexate can be increased when it is combined with Haloperidol.Approved
HigenamineThe serum concentration of Methotrexate can be increased when it is combined with Higenamine.Investigational
HMPL-004The serum concentration of Methotrexate can be increased when it is combined with HMPL-004.Investigational
HydrocortisoneThe serum concentration of Methotrexate can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
IbuprofenThe serum concentration of Methotrexate can be increased when it is combined with Ibuprofen.Approved
IbuproxamThe serum concentration of Methotrexate can be increased when it is combined with Ibuproxam.Withdrawn
IcatibantThe serum concentration of Methotrexate can be increased when it is combined with Icatibant.Approved
IdelalisibThe serum concentration of Methotrexate can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Methotrexate can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Methotrexate can be increased when it is combined with Imipramine.Approved
IndinavirThe serum concentration of Methotrexate can be decreased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Methotrexate can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenThe serum concentration of Methotrexate can be increased when it is combined with Indoprofen.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Methotrexate is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Methotrexate is combined with INGN 225.Investigational
IsavuconazoniumThe serum concentration of Methotrexate can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoxicamThe serum concentration of Methotrexate can be increased when it is combined with Isoxicam.Withdrawn
ItraconazoleThe serum concentration of Methotrexate can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Methotrexate can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Methotrexate can be increased when it is combined with Ivermectin.Approved, Vet Approved
KebuzoneThe serum concentration of Methotrexate can be increased when it is combined with Kebuzone.Experimental
KetamineThe serum concentration of Methotrexate can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Methotrexate can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe serum concentration of Methotrexate can be increased when it is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe serum concentration of Methotrexate can be increased when it is combined with Ketorolac.Approved
LansoprazoleThe serum concentration of Methotrexate can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Methotrexate can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Methotrexate is combined with Leflunomide.Approved, Investigational
LevofloxacinThe serum concentration of Methotrexate can be increased when it is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Methotrexate can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Methotrexate can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Methotrexate can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Methotrexate can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Methotrexate can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineThe serum concentration of Methotrexate can be increased when it is combined with Lisofylline.Investigational
LomitapideThe serum concentration of Methotrexate can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Methotrexate can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Methotrexate can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Methotrexate can be increased when it is combined with Loratadine.Approved
LornoxicamThe serum concentration of Methotrexate can be increased when it is combined with Lornoxicam.Approved
LosartanThe serum concentration of Methotrexate can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Methotrexate can be increased when it is combined with Lovastatin.Approved, Investigational
LoxoprofenThe serum concentration of Methotrexate can be increased when it is combined with Loxoprofen.Approved
LumacaftorThe serum concentration of Methotrexate can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe serum concentration of Methotrexate can be increased when it is combined with Lumiracoxib.Approved, Investigational
Magnesium salicylateThe serum concentration of Methotrexate can be increased when it is combined with Magnesium salicylate.Approved
MaprotilineThe serum concentration of Methotrexate can be increased when it is combined with Maprotiline.Approved
MasoprocolThe serum concentration of Methotrexate can be increased when it is combined with Masoprocol.Approved
MebendazoleThe serum concentration of Methotrexate can be increased when it is combined with Mebendazole.Approved, Vet Approved
Meclofenamic acidThe serum concentration of Methotrexate can be increased when it is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe serum concentration of Methotrexate can be increased when it is combined with Mefenamic acid.Approved
MefloquineThe serum concentration of Methotrexate can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Methotrexate can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamThe serum concentration of Methotrexate can be increased when it is combined with Meloxicam.Approved, Vet Approved
MeprobamateThe serum concentration of Methotrexate can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineThe serum concentration of Methotrexate can be increased when it is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Methotrexate is combined with Metamizole.Withdrawn
MethadoneThe serum concentration of Methotrexate can be increased when it is combined with Methadone.Approved
MeticillinThe serum concentration of Methotrexate can be increased when it is combined with Meticillin.Approved
MetoprololThe serum concentration of Methotrexate can be increased when it is combined with Metoprolol.Approved, Investigational
MezlocillinThe serum concentration of Methotrexate can be increased when it is combined with Mezlocillin.Approved
MibefradilThe serum concentration of Methotrexate can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Methotrexate can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Methotrexate can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Methotrexate can be decreased when it is combined with Mifepristone.Approved, Investigational
MipomersenMipomersen may increase the hepatotoxic activities of Methotrexate.Approved
MitomycinThe serum concentration of Methotrexate can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Methotrexate can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MizoribineThe serum concentration of Methotrexate can be increased when it is combined with Mizoribine.Investigational
MorphineThe serum concentration of Methotrexate can be increased when it is combined with Morphine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Methotrexate can be increased when it is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe serum concentration of Methotrexate can be increased when it is combined with Mycophenolic acid.Approved
NabumetoneThe serum concentration of Methotrexate can be increased when it is combined with Nabumetone.Approved
NafamostatThe serum concentration of Methotrexate can be increased when it is combined with Nafamostat.Approved, Investigational
NafcillinThe serum concentration of Methotrexate can be increased when it is combined with Nafcillin.Approved
NaftifineThe serum concentration of Methotrexate can be increased when it is combined with Naftifine.Approved
NaltrexoneThe serum concentration of Methotrexate can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe serum concentration of Methotrexate can be increased when it is combined with Naproxen.Approved, Vet Approved
NaringeninThe serum concentration of Methotrexate can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Methotrexate is combined with Natalizumab.Approved, Investigational
NCX 4016The serum concentration of Methotrexate can be increased when it is combined with NCX 4016.Investigational
NefazodoneThe serum concentration of Methotrexate can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Methotrexate can be decreased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Methotrexate can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacThe serum concentration of Methotrexate can be increased when it is combined with Nepafenac.Approved
NicardipineThe serum concentration of Methotrexate can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Methotrexate can be decreased when it is combined with Nifedipine.Approved
Niflumic AcidThe serum concentration of Methotrexate can be increased when it is combined with Niflumic Acid.Approved
NilotinibThe serum concentration of Methotrexate can be increased when it is combined with Nilotinib.Approved, Investigational
NimesulideThe serum concentration of Methotrexate can be increased when it is combined with Nimesulide.Approved, Withdrawn
NisoldipineThe serum concentration of Methotrexate can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Methotrexate can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Methotrexate can be increased when it is combined with Nitrendipine.Approved
NitroaspirinThe serum concentration of Methotrexate can be increased when it is combined with Nitroaspirin.Investigational
NorethisteroneThe serum concentration of Methotrexate can be decreased when it is combined with Norethisterone.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Methotrexate.Experimental
OlopatadineThe serum concentration of Methotrexate can be increased when it is combined with Olopatadine.Approved
OlsalazineThe serum concentration of Methotrexate can be increased when it is combined with Olsalazine.Approved
OmeprazoleThe serum concentration of Methotrexate can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe serum concentration of Methotrexate can be increased when it is combined with Orgotein.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Methotrexate.Approved
OxacillinThe serum concentration of Methotrexate can be increased when it is combined with Oxacillin.Approved
OxaprozinThe serum concentration of Methotrexate can be increased when it is combined with Oxaprozin.Approved
OxyphenbutazoneThe serum concentration of Methotrexate can be increased when it is combined with Oxyphenbutazone.Withdrawn
P-NitrophenolThe serum concentration of Methotrexate can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Methotrexate.Approved, Vet Approved
Palmitic AcidThe serum concentration of Methotrexate can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Methotrexate can be increased when it is combined with Pantoprazole.Approved
ParecoxibThe serum concentration of Methotrexate can be increased when it is combined with Parecoxib.Approved
ParoxetineThe serum concentration of Methotrexate can be increased when it is combined with Paroxetine.Approved, Investigational
PerindoprilThe serum concentration of Methotrexate can be increased when it is combined with Perindopril.Approved
PhenobarbitalThe serum concentration of Methotrexate can be decreased when it is combined with Phenobarbital.Approved
PhenoxymethylpenicillinThe serum concentration of Methotrexate can be increased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazoneThe serum concentration of Methotrexate can be increased when it is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Methotrexate.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Methotrexate.Approved, Investigational
PimozideThe serum concentration of Methotrexate can be increased when it is combined with Pimozide.Approved
PiperacillinThe serum concentration of Methotrexate can be increased when it is combined with Piperacillin.Approved
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Methotrexate.Experimental
PirfenidoneThe serum concentration of Methotrexate can be increased when it is combined with Pirfenidone.Investigational
PiroxicamThe serum concentration of Methotrexate can be increased when it is combined with Piroxicam.Approved, Investigational
PivampicillinThe serum concentration of Methotrexate can be increased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Methotrexate can be increased when it is combined with Pivmecillinam.Approved
Platelet Activating FactorThe serum concentration of Methotrexate can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Methotrexate can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Methotrexate can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Methotrexate can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Methotrexate can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Methotrexate can be increased when it is combined with Prednisone.Approved, Vet Approved
ProbenecidThe serum concentration of Methotrexate can be increased when it is combined with Probenecid.Approved
Procaine benzylpenicillinThe serum concentration of Methotrexate can be increased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
ProgesteroneThe serum concentration of Methotrexate can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Methotrexate can be increased when it is combined with Promethazine.Approved
PropacetamolThe serum concentration of Methotrexate can be increased when it is combined with Propacetamol.Approved
PropafenoneThe serum concentration of Methotrexate can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Methotrexate can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Methotrexate can be increased when it is combined with Protriptyline.Approved
PTC299The serum concentration of Methotrexate can be increased when it is combined with PTC299.Investigational
QuercetinThe serum concentration of Methotrexate can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Methotrexate can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Methotrexate can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Methotrexate can be increased when it is combined with Quinine.Approved
RabeprazoleThe serum concentration of Methotrexate can be increased when it is combined with Rabeprazole.Approved, Investigational
Rabies vaccineThe risk or severity of adverse effects can be increased when Methotrexate is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Methotrexate.Approved
RanitidineThe serum concentration of Methotrexate can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Methotrexate can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Methotrexate can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Methotrexate can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Methotrexate can be decreased when it is combined with Reserpine.Approved
ResveratrolThe serum concentration of Methotrexate can be increased when it is combined with Resveratrol.Experimental, Investigational
RifampicinThe serum concentration of Methotrexate can be decreased when it is combined with Rifampicin.Approved
RilpivirineThe serum concentration of Methotrexate can be increased when it is combined with Rilpivirine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Methotrexate is combined with CDX-110.Investigational
RitonavirThe serum concentration of Methotrexate can be decreased when it is combined with Ritonavir.Approved, Investigational
RofecoxibThe serum concentration of Methotrexate can be increased when it is combined with Rofecoxib.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Methotrexate.Approved
RolapitantThe serum concentration of Methotrexate can be increased when it is combined with Rolapitant.Approved
SalicylamideThe serum concentration of Methotrexate can be increased when it is combined with Salicylamide.Approved
Salicylic acidThe serum concentration of Methotrexate can be increased when it is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe serum concentration of Methotrexate can be increased when it is combined with Salsalate.Approved
SapropterinThe serum concentration of Sapropterin can be decreased when it is combined with Methotrexate.Approved, Investigational
SaquinavirThe serum concentration of Methotrexate can be decreased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Methotrexate can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Methotrexate can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SeratrodastThe serum concentration of Methotrexate can be increased when it is combined with Seratrodast.Approved, Investigational
SertralineThe serum concentration of Methotrexate can be increased when it is combined with Sertraline.Approved
SimeprevirThe serum concentration of Methotrexate can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Methotrexate can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Methotrexate.Approved
SirolimusThe serum concentration of Methotrexate can be decreased when it is combined with Sirolimus.Approved, Investigational
SorafenibThe serum concentration of Methotrexate can be increased when it is combined with Sorafenib.Approved, Investigational
SpironolactoneThe serum concentration of Methotrexate can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Methotrexate is combined with SRP 299.Investigational
SRT501The serum concentration of Methotrexate can be increased when it is combined with SRT501.Investigational
St. John's WortThe serum concentration of Methotrexate can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Methotrexate can be increased when it is combined with Staurosporine.Experimental
StreptozocinThe serum concentration of Methotrexate can be decreased when it is combined with Streptozocin.Approved
SulbactamThe serum concentration of Methotrexate can be increased when it is combined with Sulbactam.Approved
SulfadiazineThe risk or severity of adverse effects can be increased when Sulfadiazine is combined with Methotrexate.Approved, Vet Approved
SulfamethoxazoleThe risk or severity of adverse effects can be increased when Sulfamethoxazole is combined with Methotrexate.Approved
SulfasalazineSulfasalazine may increase the hepatotoxic activities of Methotrexate.Approved
SulfinpyrazoneThe serum concentration of Methotrexate can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe risk or severity of adverse effects can be increased when Sulfisoxazole is combined with Methotrexate.Approved, Vet Approved
SulindacThe serum concentration of Methotrexate can be increased when it is combined with Sulindac.Approved
SultamicillinThe serum concentration of Methotrexate can be increased when it is combined with Sultamicillin.Investigational
SumatriptanThe serum concentration of Methotrexate can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Methotrexate can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenThe serum concentration of Methotrexate can be increased when it is combined with Suprofen.Approved, Withdrawn
TacrineThe serum concentration of Methotrexate can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Methotrexate.Approved, Investigational
TacrolimusThe serum concentration of Methotrexate can be decreased when it is combined with Tacrolimus.Approved, Investigational
TAK-390MRThe serum concentration of Methotrexate can be increased when it is combined with TAK-390MR.Investigational
TamoxifenThe serum concentration of Methotrexate can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Methotrexate can be increased when it is combined with Taurocholic Acid.Experimental
TazobactamThe serum concentration of Methotrexate can be increased when it is combined with Tazobactam.Approved
TegafurThe risk or severity of adverse effects can be increased when Methotrexate is combined with Tegafur.Approved
TelmisartanThe serum concentration of Methotrexate can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Methotrexate can be increased when it is combined with Temsirolimus.Approved
TenoxicamThe serum concentration of Methotrexate can be increased when it is combined with Tenoxicam.Approved
TepoxalinThe serum concentration of Methotrexate can be increased when it is combined with Tepoxalin.Vet Approved
TerazosinThe serum concentration of Methotrexate can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Methotrexate can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Methotrexate can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Methotrexate can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Methotrexate can be increased when it is combined with Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Methotrexate is combined with TG4010.Investigational
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Methotrexate.Approved
Tiaprofenic acidThe serum concentration of Methotrexate can be increased when it is combined with Tiaprofenic acid.Approved
TicagrelorThe serum concentration of Methotrexate can be increased when it is combined with Ticagrelor.Approved
TicarcillinThe serum concentration of Methotrexate can be increased when it is combined with Ticarcillin.Approved, Vet Approved
TinoridineThe serum concentration of Methotrexate can be increased when it is combined with Tinoridine.Investigational
TofacitinibMethotrexate may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
Tolfenamic AcidThe serum concentration of Methotrexate can be increased when it is combined with Tolfenamic Acid.Approved
TolmetinThe serum concentration of Methotrexate can be increased when it is combined with Tolmetin.Approved
TolvaptanThe serum concentration of Methotrexate can be increased when it is combined with Tolvaptan.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Methotrexate.Approved
TranilastThe serum concentration of Methotrexate can be increased when it is combined with Tranilast.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Methotrexate.Approved, Investigational
TrazodoneThe serum concentration of Methotrexate can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Methotrexate can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Methotrexate can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe risk or severity of adverse effects can be increased when Trimethoprim is combined with Methotrexate.Approved, Vet Approved
TrimipramineThe serum concentration of Methotrexate can be increased when it is combined with Trimipramine.Approved
Trisalicylate-cholineThe serum concentration of Methotrexate can be increased when it is combined with Trisalicylate-choline.Approved
TroleandomycinThe serum concentration of Methotrexate can be increased when it is combined with Troleandomycin.Approved
ValdecoxibThe serum concentration of Methotrexate can be increased when it is combined with Valdecoxib.Investigational, Withdrawn
VenlafaxineThe serum concentration of Methotrexate can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Methotrexate can be decreased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Methotrexate can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Methotrexate can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Methotrexate can be increased when it is combined with Vinorelbine.Approved, Investigational
ZaltoprofenThe serum concentration of Methotrexate can be increased when it is combined with Zaltoprofen.Approved
ZileutonThe serum concentration of Methotrexate can be increased when it is combined with Zileuton.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Methotrexate can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracThe serum concentration of Methotrexate can be increased when it is combined with Zomepirac.Withdrawn
Food Interactions
  • Milk appears to reduce its absorption.
  • Take without regard to meals. Limit caffeine intake.
References
Synthesis Reference

DrugSyn.org

US2512572
General References
  1. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004 Feb 28;363(9410):675-81. [PubMed:15001324 ]
  2. Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H: The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005 Feb;114(2):154-63. [PubMed:15639649 ]
External Links
ATC CodesL01BA01L04AX03
AHFS Codes
  • 10:00.00
PDB Entries
FDA labelDownload (518 KB)
MSDSDownload (77 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentMalignant Neoplasm of Fourth Ventricle of Brain / Tumor, Brain1
0CompletedTreatmentTransplantation, Stem Cell1
0RecruitingTreatmentBrain Tumor Recurrent1
0WithdrawnTreatmentBrain and Central Nervous System Tumors / Lymphoma NOS / Neurotoxicity1
1Active Not RecruitingTreatmentAcute Myeloid Leukaemias (AML)1
1Active Not RecruitingTreatmentLymphoma NOS / Mantle Cell Lymphoma (MCL)1
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of 7-hydroxymethotrexate / Pharmacokinetics of Isavuconazole / Pharmacokinetics of Methotrexate1
1CompletedNot AvailablePsoriasis1
1CompletedNot AvailableRheumatoid Arthritis1
1CompletedBasic ScienceRheumatoid Arthritis2
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Mixed Phenotype Acute Leukemia (MPAL) / Myelodysplastic Syndromes (MDS)1
1CompletedTreatmentAcute and Chronic Inflammation / Autoimmune Diseases / Disorder of Pleura and Pleural Cavity / Disorder of Synovium / Felty's Syndrome / Rheumatoid Arthritis / Rheumatoid Nodules / Sjogren's Syndrome1
1CompletedTreatmentBrain and Central Nervous System Tumors / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentCentral Nervous System Lymphoma / Intraocular Lymphoma1
1CompletedTreatmentChildhood B Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma1
1CompletedTreatmentCongenital Hypoplastic Anemia1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentLeukemia, Lymphoblastic, Acute / Leukemia, Myeloid, Acute1
1CompletedTreatmentLeukemias / Lymphoma NOS1
1CompletedTreatmentLeukemias / Myelodysplastic Syndrome1
1CompletedTreatmentLymphoblastic Leukemia, Acute, Childhood / Myelogenous Leukemia, Acute, Childhood1
1CompletedTreatmentLymphoma NOS1
1CompletedTreatmentMalaria1
1CompletedTreatmentMetastatic Breast Cancer (MBC)1
1CompletedTreatmentNeuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentRheumatoid Arthritis11
1CompletedTreatmentSarcomas2
1CompletedTreatmentSchizoaffective Disorders / Schizophrenia / Schizophreniform Disorder1
1RecruitingNot AvailablePsoriasis / Rheumatoid Arthritis1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Non-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B-cell Adult Acute Lymphoblastic Leukemia / Lymphoma, Lymphoblastic / T-cell Adult Acute Lymphoblastic Leukemia1
1RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukaemias (AML) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myeloid Leukemia (CML) / Lymphoma, Hodgkins / Malignancies, Hematologic / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myelofibrosis / Myeloproliferative Syndromes / Non Hodgkin Lymphoma (NHL)1
1RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome1
1RecruitingTreatmentContiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia1
1RecruitingTreatmentGraft Versus Host Disease (GVHD) / Sickle Cells Disease1
1RecruitingTreatmentLeukemia, Lymphoid / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Myelofibrosis / Myeloid Leukemias / Waldenstrom's Macroglobulinemia (WM)1
1RecruitingTreatmentLeukemia, Plasma Cell / Recurrent Plasma Cell Myeloma1
1RecruitingTreatmentLymphoblastic Leukemia, Acute, Childhood / Lymphoma, Lymphoblastic / Peripheral T-Cell Lymphoma (PTCL)1
1RecruitingTreatmentMalignant Neoplasm of Fourth Ventricle of Brain / Tumor, Brain1
1RecruitingTreatmentRheumatoid Arthritis2
1TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Recurrent Pediatric ALL / Refractory Pediatric ALL / Relapsed Pediatric ALL1
1TerminatedTreatmentAcute Myeloid Leukaemias (AML) / Juvenile Myelomonocytic Leukemia / Myelodysplastic Syndrome1
1TerminatedTreatmentAllergy to Native e.Coli Asparaginase / Allergy to PEG e.Coli Asparaginase / Relapsed Acute Lymphoblastic Leukemia1
1TerminatedTreatmentLeukemia, Lymphoblastic, Acute / Leukemia, Lymphoblastic, Acute, T Cell / Lymphoblastic Leukemia, Acute / Lymphoblastic Leukemia, Acute, Childhood1
1TerminatedTreatmentRheumatoid Arthritis1
1Unknown StatusNot AvailableChild Mortality1
1Unknown StatusSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
1Unknown StatusTreatmentMelanoma (Skin)1
1WithdrawnBasic ScienceRheumatoid Arthritis1
1, 2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
1, 2Active Not RecruitingTreatmentLeukemias1
1, 2Active Not RecruitingTreatmentRecurrent Childhood Acute Lymphoblastic Leukemia1
1, 2CompletedPreventionMalignancies, Hematologic1
1, 2CompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1, 2CompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1, 2CompletedTreatmentActive Rheumatoid Arthritis1
1, 2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1, 2CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemias1
1, 2CompletedTreatmentAcute Undifferentiated Leukemia (AUL) / B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / L1 Adult Acute Lymphoblastic Leukemia / L1 Childhood Acute Lymphoblastic Leukemia / L2 Adult Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
1, 2CompletedTreatmentBrain and Central Nervous System Tumors / Lymphoma NOS1
1, 2CompletedTreatmentCancer, Breast1
1, 2CompletedTreatmentChemotherapeutic Agent Toxicity / Lymphoma NOS / Mucositis / Neurotoxicity1
1, 2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias / Lymphoma NOS1
1, 2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Precancerous Conditions1
1, 2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1, 2CompletedTreatmentLeukemias3
1, 2CompletedTreatmentLeukemias / Lymphoma NOS1
1, 2CompletedTreatmentLymphoma NOS1
1, 2CompletedTreatmentPsoriasis1
1, 2CompletedTreatmentRheumatoid Arthritis1
1, 2CompletedTreatmentSystemic Sclerosis1
1, 2Not Yet RecruitingTreatmentAdult Burkitt Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Diffuse Large B-Cell Lymphoma (DLBCL) / MYC Gene Mutation / Plasmablastic Lymphoma1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
1, 2RecruitingTreatmentAcute Myeloid Leukaemias (AML)1
1, 2RecruitingTreatmentCancer, Breast1
1, 2RecruitingTreatmentCentral Nervous System Lymphoma1
1, 2RecruitingTreatmentLeukemias2
1, 2RecruitingTreatmentLeukemias / Lymphoma NOS1
1, 2RecruitingTreatmentRefractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) / Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)1
1, 2SuspendedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1, 2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Precursor B-Cell Lymphoblastic Leukemia / Precursor T-Cell Lymphoblastic Leukemia1
1, 2TerminatedTreatmentAnaplastic Large Cell Lymphoma / Recurrent Childhood Anaplastic Large Cell Lymphoma1
1, 2TerminatedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1, 2TerminatedTreatmentLeukemias1
1, 2TerminatedTreatmentNon-Infectious Intermediate and Posterior Uveitis1
1, 2TerminatedTreatmentRelapsed T-Cell Acute Lymphoblastic Leukemia / Relapsed T-Cell Lymphoblastic Lymphoma1
1, 2TerminatedTreatmentDiffuse posterior uveitis / Uveitis, Intermediate1
1, 2WithdrawnSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes1
1, 2WithdrawnTreatmentBrain and Central Nervous System Tumors / Cancer, Breast / Cognitive/Functional Effects / Drug/Agent Toxicity by Tissue/Organ / Psychosocial Effects of Cancer and Its Treatment1
1, 2WithdrawnTreatmentLymphoma NOS1
2Active Not RecruitingPreventionAcute Graft Versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation / Hematopoietic Stem Cell Transplantation (HSCT)1
2Active Not RecruitingPreventionChronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Follicular Lymphoma (FL) / Leukaemia, Acute / Lymphoma, B-Cell / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse / Myelodysplasia / Small Lymphocytic Lymphoma (SLL)1
2Active Not RecruitingSupportive CareAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome1
2Active Not RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Acute Biphenotypic Leukemia (ABL) / Acute Leukemias of Ambiguous Lineage / Acute Myeloid Leukemia in Remission / Acute Undifferentiated Leukemia (AUL) / Adult Acute Lymphoblastic Leukemia in Remission / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / RAEB-1 / RAEB-2 / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Refractory Adult Acute Lymphoblastic Leukemia / Refractory Anemia With Excess Blasts / Refractory Childhood Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Aplastic Anaemia (AA) / Burkitt's Lymphoma / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Congenital Amegakaryocytic Thrombocytopenia / Congenital Hypoplastic Anemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Juvenile Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Paroxysmal Nocturnal Hemoglobinuria (PNH) / Peripheral T-Cell Lymphoma (PTCL) / Polycythemia Vera (PV) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Secondary Myelofibrosis / Severe Combined Immunodeficiency / Severe Congenital Neutropenia / Shwachman-Diamond Syndrome / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Waldenstrom's Macroglobulinemia (WM) / Wiskott-Aldrich Syndrome (WAS)1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)2
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2Active Not RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome RAEB 1 / Myelodysplastic Syndrome RAEB 21
2Active Not RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukaemias (AML) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myeloid Leukemia (CML) / Leukemias / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloproliferative Diseases / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia in Remission1
2Active Not RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult L1 Acute Lymphoblastic Leukemia / Adult L2 Acute Lymphoblastic Leukemia / Adult T Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAdult Acute Megakaryoblastic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With Maturation / Adult Acute Myeloid Leukemia With Minimal Differentiation / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Acute Myelomonocytic Leukemia / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / De Novo Myelodysplastic Syndrome / Myelodysplastic Syndrome With Excess Blasts / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22)1
2Active Not RecruitingTreatmentAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Ph Positive Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentCentral Nervous System Lymphoma1
2Active Not RecruitingTreatmentChemotherapeutic Agent Toxicity / Cognitive/Functional Effects / Lymphoma NOS / Neurotoxicity / Radiation Toxicity1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Diffuse, Large B-Cell, Lymphoma / Lymphoma, Hodgkins / Lymphoma, Low-Grade / Lymphoma, Mantle-Cell / Small Lymphocytic Lymphoma (SLL) / T-Cell Lymphomas1
2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Precancerous/Nonmalignant Condition1
2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD)1
2Active Not RecruitingTreatmentLeukaemia, Lymphoblastic / Lymphoma, Lymphoblastic1
2Active Not RecruitingTreatmentLeukemias3
2Active Not RecruitingTreatmentLeukemias / Lymphoma NOS2
2Active Not RecruitingTreatmentLeukemias / Lymphoma NOS / Transplantation, Stem Cell1
2Active Not RecruitingTreatmentLymphoma NOS3
2Active Not RecruitingTreatmentMalignant Fibrous Histiocytoma (MFH) of Bone / Osteosarcomas1
2Active Not RecruitingTreatmentNasal Type Extranodal NK/T-Cell Lymphoma1
2Active Not RecruitingTreatmentUlcerative Colitis (UC)1
2Active Not RecruitingTreatmentUntreated Childhood Medulloblastoma1
2CompletedNot AvailableCancer, Breast1
2CompletedBasic ScienceRheumatoid Arthritis1
2CompletedDiagnosticAdjuvant Arthritis / Rheumatoid Arthritis1
2CompletedPreventionAcute Graft Versus Host Disease1
2CompletedSupportive CareAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Atypical Chronic Myeloid Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Eosinophilic Leukemia (CEL) / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Extramedullary Plasmacytoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Graft Versus Host Disease (GVHD) / Hematopoietic/Lymphoid Cancer / Isolated Plasmacytoma of Bone / Juvenile Myelomonocytic Leukemia / Meningeal Chronic Myelogenous Leukemia / Myelodysplastic/Myeloproliferative Disease, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Multiple Myeloma / Stage I Mycosis Fungoides/Sezary Syndrome / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Multiple Myeloma / Stage II Mycosis Fungoides/Sezary Syndrome / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma1
2CompletedSupportive CareAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Grade III Lymphomatoid Granulomatosis / B-Cell Chronic Lymphocytic Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Graft Versus Host Disease (GVHD) / Intraocular Lymphoma / Myelodysplastic Syndrome With Isolated Del(5q) / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Post-Transplant Lymphoproliferative Disorder / Primary Central Nervous System Hodgkin Lymphoma / Primary Central Nervous System Non-Hodgkin Lymphoma / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ringed Sideroblasts / Refractory Chronic Lymphocytic Leukemia / Refractory Cytopenia With Multilineage Dysplasia / Refractory Hairy Cell Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Central Nervous System Hodgkin Lymphoma / Secondary Central Nervous System Non-Hodgkin Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedSupportive CareAcute Lymphoblastic Leukaemias (ALL)1
2CompletedSupportive CareCancers1
2CompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Infection NOS / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Precancerous Conditions / Secondary Myelofibrosis / Small Intestine Cancer1
2CompletedTreatmentAll / AML / Aplastic Anaemia (AA) / CLL / CML Chronic Phase, Accelerated Phase, or Blast Crisis / MDS / Multiple Myeloma (MM) / MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET) / RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Acute Promyelocytic Leukemia (M3) / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Burkitt's Lymphoma / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myeloid Leukemia in Remission / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Acute Promyelocytic Leukemia (M3) / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / De Novo Myelodysplastic Syndromes / Hematopoietic/Lymphoid Cancer / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Relapsing Chronic Myelogenous Leukemia1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)3
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
2CompletedTreatmentAcute Lymphoblastic Leukemia, Mature B-Cell / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentAcute Lymphocytic Leukemia (ALL)1
2CompletedTreatmentAdult Acute Lymphoblastic Leukemia in Remission1
2CompletedTreatmentAdult-Onset Still's Disease1
2CompletedTreatmentAplastic Anaemia (AA)2
2CompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentBladder Cancers3
2CompletedTreatmentBladder Cancers / Muscle-invasive Bladder Cancer1
2CompletedTreatmentBrain and Central Nervous System Tumors3
2CompletedTreatmentBurkitt's Lymphoma / Burkitt'S-like Lymphoma1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentCancer, Breast / Cancer, Ovarian1
2CompletedTreatmentCancer, Breast / Neoplasms, Breast1
2CompletedTreatmentCancer, Ovarian / Extragonadal Germ Cell Tumor1
2CompletedTreatmentCentral Nervous System Lymphoma1
2CompletedTreatmentCentral Nervous System Metastases / Leptomeningeal Metastases / Recurrent Breast Cancer / Stage IV Breast Cancer / Tumors Metastatic to Brain1
2CompletedTreatmentCentral Nervous System Tumor, Pediatric1
2CompletedTreatmentChildhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Untreated Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentChronic Myelogenous Leukemia (CML) / Leukemias1
2CompletedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentCongenital Amegakaryocytic Thrombocytopenia / Congenital Hypoplastic Anemia / Leukemias / Myelodysplastic Syndromes / Severe Congenital Neutropenia1
2CompletedTreatmentDesmoid Tumors1
2CompletedTreatmentEstrogen Receptor-negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / HER2-positive Breast Cancer / Progesterone Receptor-negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer1
2CompletedTreatmentEstrogen Receptor-negative Breast Cancer / Progesterone Receptor-negative Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentGiant Cell Arteritis1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Lymphoma NOS1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Malignancies, Hematologic2
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Transplantation, Bone Marrow1
2CompletedTreatmentHead and Neck Cancers1
2CompletedTreatmentHigh Risk Urothelial Carcinoma of the Upper Urinary Tracts / Muscle Invasive Bladder Cancer1
2CompletedTreatmentHodgkins Disease (HD)2
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentIntraluminal Pulmonary Vein Stenosis1
2CompletedTreatmentKidney Cancer1
2CompletedTreatmentKidney Cancer / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Myeloproliferative Disorders1
2CompletedTreatmentLangerhans Cell Histiocytosis (LCH)1
2CompletedTreatmentLeptomeningeal Metastasis / Metastases, Brain / Neoplasms, Breast1
2CompletedTreatmentLeukemia, Lymphocytic, Acute1
2CompletedTreatmentLeukemias22
2CompletedTreatmentLeukemias / Lymphoma NOS7
2CompletedTreatmentLeukemias / Lymphoma NOS / Lymphoproliferative Disorders / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentLeukemias / Lymphoma NOS / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Myeloproliferative Neoplasms / Plasma Cell Neoplasms1
2CompletedTreatmentLeukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2CompletedTreatmentLeukemias / Lymphoma NOS / Myelodysplastic Syndrome1
2CompletedTreatmentLeukemias / Lymphoma NOS / Myelodysplastic Syndromes1
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes4
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms2
2CompletedTreatmentLeukemias / Neutropenias / Thrombocytopenias1
2CompletedTreatmentLymphohistiocytosis, Hemophagocytic1
2CompletedTreatmentLymphoma NOS20
2CompletedTreatmentLymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm2
2CompletedTreatmentLymphoma, B Cell1
2CompletedTreatmentMetastatic Osteosarcoma1
2CompletedTreatmentMultiple Myeloma (MM)1
2CompletedTreatmentMultiple Myeloma (MM) / Plasma Cell Neoplasms1
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2CompletedTreatmentMyasthenia Gravis1
2CompletedTreatmentNeuroendocrine Carcinoma of the Skin1
2CompletedTreatmentNeurofibromatosis Type 1 / Precancerous Conditions1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)2
2CompletedTreatmentOsteosarcomas1
2CompletedTreatmentPsoriatic Arthritis1
2CompletedTreatmentRecurrent Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentRecurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentRheumatoid Arthritis22
2CompletedTreatmentRheumatoid Arthritis / Synovitis1
2CompletedTreatmentSarcomas1
2CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2CompletedTreatmentUlcerative Colitis (UC)1
2CompletedTreatmentUveitis1
2CompletedTreatmentInflammatory processes / Vasculitis / Wegener Granulomatosis (WG)1
2Enrolling by InvitationTreatmentAcute,Leukemia, Lymphoid1
2Enrolling by InvitationTreatmentGraft Versus Host Disease (GVHD)1
2Not Yet RecruitingPreventionGraft Versus Host Disease (GVHD)1
2Not Yet RecruitingTreatmentLabor; Forced or Induced, Affecting Fetus or Newborn1
2Not Yet RecruitingTreatmentRheumatoid Arthritis1
2RecruitingNot AvailableCoronary Artery Disease1
2RecruitingPreventionGraft Versus Host Disease (GVHD) / Hematopoietic Stem Cell Transplantation (HSCT)1
2RecruitingPreventionGraft Versus Host Disease (GVHD) / Neoplasms, Hematologic / Non-Neoplastic Hematologic and Lymphocytic Disorder1
2RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Acute Biphenotypic Leukemia (ABL) / Acute Leukemias of Ambiguous Lineage / Acute Undifferentiated Leukemia (AUL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Graft Versus Host Disease (GVHD) / Lymphoma, Lymphoblastic / Myelodysplastic Syndrome With Excess Blasts / Myelodysplastic Syndrome With Excess Blasts-1 / Myelodysplastic Syndrome With Excess Blasts-2 / RAEB-1 / RAEB-2 / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Anemia With Excess Blasts1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Children1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia, B-Cell / Leukemia, T-Cell / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Adult Lymphoblastic Lymphoma1
2RecruitingTreatmentAcute Myeloid Leukaemias (AML)1
2RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Chronic Myelogenous Leukemia (CML) / Chronic Myelomonocytic Leukemia (CMML) / Myelodysplastic Syndromes (MDS)1
2RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome2
2RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndromes (MDS)1
2RecruitingTreatmentAll1
2RecruitingTreatmentAtherosclerosis / HIV Disease / Inflammatory processes1
2RecruitingTreatmentAtypical Teratoid Rhabdoid Tumors (ATRT) / Malignant Rhabdoid Tumors (MRT)1
2RecruitingTreatmentB Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative / Philadelphia Chromosome Positive / Recurrent Adult Acute Lymphoblastic Leukemia / Refractory Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2RecruitingTreatmentB-cell Acute Lymphoblastic Leukemia1
2RecruitingTreatmentBladder Cancers1
2RecruitingTreatmentBrain and Central Nervous System Tumors1
2RecruitingTreatmentCancers / Leukemias / Lymphoma NOS1
2RecruitingTreatmentColorectal Cancers1
2RecruitingTreatmentDe Novo / Low-dose Corticosteroids Pretreatment / Secondary / Untreated Philadelphia Positive Acute Lymphoblastic Leukemia1
2RecruitingTreatmentDiffuse Large B Cell Lymphoma (DLBCL)1
2RecruitingTreatmentDiffuse Large B-Cell Lymphoma (DLBCL)1
2RecruitingTreatmentEpstein Barr Virus Associated Hodgkin's Lymphoma / Epstein Barr Virus Associated Non Hodgkin's Lymphoma / Post-transplant Lymphoproliferative Disease (PTLD)1
2RecruitingTreatmentHigh Grade Osteosarcoma1
2RecruitingTreatmentLangerhans Cell Histiocytosis (LCH)1
2RecruitingTreatmentLarge B-cell Diffuse Lymphoma of Testis / Primary Testicular Diffuse Large B-cell Lymphoma1
2RecruitingTreatmentLarge Granular Lymphocytes Leukemia1
2RecruitingTreatmentLeptomeningeal Metastasis1
2RecruitingTreatmentLeukaemia, Lymphoblastic1
2RecruitingTreatmentLeukemia, Lymphoblastic, Acute / Leukemias / Lymphoma, Lymphoblastic1
2RecruitingTreatmentLeukemias6
2RecruitingTreatmentLeukemias / Lymphoma NOS / Lymphoma, Lymphoblastic / Precursor-B Acute Lymphoblastic Leukemia1
2RecruitingTreatmentLocalized Urothelial Carcinoma of the Renal Pelvis and Ureter / Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter / Regional Urothelial Carcinoma of the Renal Pelvis and Ureter1
2RecruitingTreatmentLymphoma NOS1
2RecruitingTreatmentLymphoma NOS / Lymphoma, Mantle-Cell1
2RecruitingTreatmentLymphoma, AIDS Related / Neoplasms, Brain1
2RecruitingTreatmentMalignant Pleural Mesothelioma (MPM) / Mesothelioma1
2RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2RecruitingTreatmentNon-Malignant1
2RecruitingTreatmentOsteosarcomas1
2RecruitingTreatmentPrimary CNS Lymphoma1
2RecruitingTreatmentPrimary Central Nervous System Lymphoma (PCNSL)1
2RecruitingTreatmentPrimary Myelofibrosis / Secondary Myelofibrosis1
2RecruitingTreatmentProgressive Desmoids Tumors1
2RecruitingTreatmentPsoriasis Vulgaris1
2RecruitingTreatmentRecurrent B-Cell Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood B-Lymphoblastic Lymphoma1
2RecruitingTreatmentRheumatoid Arthritis10
2RecruitingTreatmentSickle Cells Disease1
2RecruitingTreatmentSolid Tumours1
2RecruitingTreatmentStage I Mantle Cell Lymphoma / Stage II Contiguous Mantle Cell Lymphoma / Stage II Non-Contiguous Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2RecruitingTreatmentUrothelial Carcinoma of the Bladder1
2SuspendedTreatmentAnaplastic Large Cell Lymphoma, ALK-Positive / CD30-Positive Neoplastic Cells Present / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma1
2SuspendedTreatmentLymphoma NOS1
2SuspendedTreatmentUnrecognized Condition: Mature B or T-cell Neoplasm1
2TerminatedPreventionGraft Versus Host Disease (GVHD)1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2TerminatedTreatmentAcute Lymphoid Leukemia (ALL) / Acute Myeloid Leukaemias (AML) / Mixed Lineage Acute Leukemia1
2TerminatedTreatmentAdvanced Colorectal Cancer1
2TerminatedTreatmentAplastic Anaemia (AA)1
2TerminatedTreatmentAtypical Burkitt Lymphoma / Burkitt's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / L3 Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma1
2TerminatedTreatmentBladder Cancers3
2TerminatedTreatmentBreast Cancer, Metastatic / Cancer treatment1
2TerminatedTreatmentCancer, Breast2
2TerminatedTreatmentCardiac Toxicity / Sarcomas1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Unusual Cancers of Childhood1
2TerminatedTreatmentEstrogen Receptor-Positive Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage I Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer1
2TerminatedTreatmentExtranodal NK/T-cell Lymphoma, Nasal Type1
2TerminatedTreatmentFollicular Lymphoma (FL)1
2TerminatedTreatmentLeukemia, Lymphoblastic, Acute / Leukemia, Myelogenous, Acute / Minimal Residual Disease1
2TerminatedTreatmentLeukemias3
2TerminatedTreatmentLeukemias / Lymphoma NOS1
2TerminatedTreatmentLeukemias / Lymphoma NOS / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2TerminatedTreatmentLeukemias / Lymphoma NOS / Myelomas / Myeloproliferative Diseases1
2TerminatedTreatmentLymphoma NOS4
2TerminatedTreatmentLymphoma, Lymphoblastic1
2TerminatedTreatmentMetastatic Colorectal Cancers1
2TerminatedTreatmentOsteosarcomas / Spindle Cell Sarcoma of Bone1
2TerminatedTreatmentOvarian Carcinoma1
2TerminatedTreatmentRecurrent Adult Acute Lymphoblastic Leukemia1
2TerminatedTreatmentRheumatoid Arthritis10
2TerminatedTreatmentUrticarias1
2Unknown StatusEducational/Counseling/TrainingAnkylosing Spondylitis (AS)1
2Unknown StatusPreventionGraft Versus Host Disease (GVHD)1
2Unknown StatusTreatmentB-cell Lymphoma Refractory1
2Unknown StatusTreatmentBrain and Central Nervous System Tumors1
2Unknown StatusTreatmentBrain and Central Nervous System Tumors / Lymphoma NOS / Lymphoproliferative Disorders / Small Intestine Cancer1
2Unknown StatusTreatmentBrain and Central Nervous System Tumors / Neuroblastomas1
2Unknown StatusTreatmentCancer, Breast6
2Unknown StatusTreatmentCancer, Ovarian1
2Unknown StatusTreatmentCentral Serous Chorioretinopathy (CSC)1
2Unknown StatusTreatmentChurg-Strauss Syndrome (CSS) / Microscopic Polyangiitis / Polyarteritis Nodosa / Wegener Granulomatosis (WG)1
2Unknown StatusTreatmentFingernail Psoriasis1
2Unknown StatusTreatmentImprovement in Function / Reduction in Pain / Reduction of Inflammation1
2Unknown StatusTreatmentKidney Cancer1
2Unknown StatusTreatmentLeukemias3
2Unknown StatusTreatmentLeukemias / Lymphoma NOS1
2Unknown StatusTreatmentLymphoblastic Leukemia, Acute1
2Unknown StatusTreatmentLymphoid Blastic Phase of Chronic Myeloid Leukemia / Philadelphia Positive Acute Lymphoblastic Leukemia1
2Unknown StatusTreatmentLymphoma NOS5
2Unknown StatusTreatmentLymphoma NOS / Small Intestine Cancer1
2Unknown StatusTreatmentMesothelioma, Malignant1
2Unknown StatusTreatmentMyocardial Infarction (MI)1
2Unknown StatusTreatmentNon-Hodgkin's Lymphoma (NHL)1
2Unknown StatusTreatmentPrimary Central Nervous System Lymphoma (PCNSL)1
2Unknown StatusTreatmentPrimary Non Hodgkin Lymphoma of the Central Nervous System2
2WithdrawnPreventionAging / Inflammatory processes1
2WithdrawnSupportive CareGraft Versus Host Disease (GVHD) / Leukemias1
2WithdrawnSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes1
2WithdrawnTreatmentAnemias / Chronic Myeloproliferative Disorders / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2WithdrawnTreatmentAnterior Urethral Cancer / Localized Transitional Cell Cancer of the Renal Pelvis and Ureter / Posterior Urethral Cancer / Recurrent Bladder Cancer / Recurrent Urethral Cancer / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Stage III Bladder Cancer / Transitional Cell Carcinoma of the Bladder / Ureter Cancer / Urethral Cancer Associated With Invasive Bladder Cancer1
2WithdrawnTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2WithdrawnTreatmentBrain and Central Nervous System Tumors / Neuroblastomas / Retinoblastoma / Sarcomas1
2WithdrawnTreatmentRecurrent Breast Cancer / Stage IV Breast Cancer1
2WithdrawnTreatmentSystemic Lupus Erythematosus (SLE)1
2, 3Active Not RecruitingTreatmentChildhood B Acute Lymphoblastic Leukemia / Childhood Burkitt Leukemia / Childhood Diffuse Large Cell Lymphoma / Mediastinal (Thymic) Large B-Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma1
2, 3CompletedPreventionGraft Versus Host Disease (GVHD)1
2, 3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2, 3CompletedTreatmentAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
2, 3CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
2, 3CompletedTreatmentHeart Failure (HF) / Myocardial Ischemia1
2, 3CompletedTreatmentLeukemias / Lymphoma NOS / Myelodysplastic Syndromes1
2, 3CompletedTreatmentRheumatoid Arthritis2
2, 3Not Yet RecruitingTreatmentJuanbi Pill / Rheumatoid Arthritis1
2, 3RecruitingTreatmentAcute Myeloid Leukaemias (AML)1
2, 3RecruitingTreatmentChildhood Ependymoma1
2, 3RecruitingTreatmentLangerhans Cell Histiocytosis (LCH)1
2, 3RecruitingTreatmentLeukemias1
2, 3RecruitingTreatmentLymphoma, Lymphoblastic1
2, 3RecruitingTreatmentMature B-Cell Lymphoma1
2, 3RecruitingTreatmentMature B-cell Non-Hodgkin Lymphoma1
2, 3RecruitingTreatmentOsteosarcomas1
2, 3TerminatedTreatmentDermatomyositis1
2, 3TerminatedTreatmentFollicular Lymphoma (FL) / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma1
2, 3Unknown StatusTreatmentLeukemias1
2, 3Unknown StatusTreatmentMucopolysaccharidosis1
2, 3Unknown StatusTreatmentOsteopetrosis1
2, 3Unknown StatusTreatmentRheumatoid Arthritis1
3Active Not RecruitingNot AvailableBrain and Central Nervous System Tumors / Cognitive/Functional Effects / Long-Term Effects Secondary to Cancer Therapy in Children / Ototoxicity1
3Active Not RecruitingNot AvailableCancer, Breast1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3Active Not RecruitingTreatmentAcute Undifferentiated Leukemia (AUL) / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentAdult T Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Graft Versus Host Disease (GVHD) / L1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia / L1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentCancer, Breast1
3Active Not RecruitingTreatmentChildhood Acute Promyelocytic Leukemia (M3) / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3Active Not RecruitingTreatmentChildhood Atypical Teratoid/Rhabdoid Tumor1
3Active Not RecruitingTreatmentDisorder Related to Bone Marrow Transplantation / Leukemias / Transplantation Infection1
3Active Not RecruitingTreatmentDrug/Agent Toxicity by Tissue/Organ / Leukemias1
3Active Not RecruitingTreatmentHead and Neck Squamous Cell Cancer1
3Active Not RecruitingTreatmentLeukemias3
3Active Not RecruitingTreatmentLocalized Osteosarcoma / Metastatic Osteosarcoma1
3Active Not RecruitingTreatmentLymphoblastic Leukemia, Acute1
3Active Not RecruitingTreatmentLymphoma NOS1
3Active Not RecruitingTreatmentNeoplasms, Head and Neck / Squamous Cell Carcinoma (SCC)1
3Active Not RecruitingTreatmentPlaque Psoriasis1
3Active Not RecruitingTreatmentRecurrent or Metastatic Head and Neck Carcinoma1
3Active Not RecruitingTreatmentRheumatoid Arthritis5
3Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
3CompletedNot AvailablePsoriasis Vulgaris1
3CompletedPreventionGraft Versus Host Disease (GVHD) / Survival1
3CompletedPreventionRheumatoid Arthritis1
3CompletedSupportive CareCancer, Breast1
3CompletedSupportive CareCardiac Toxicity / Leukemias / Lymphoma NOS1
3CompletedSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS1
3CompletedTreatmentActive Rheumatoid Arthritis1
3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)2
3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelocytic Leukemia / Chronic Myelocytic Leukemia / Hodgkins Disease (HD) / Myelodysplastic Syndrome1
3CompletedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Acute Myeloid Leukemia/Transient Myeloproliferative Disorder / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Myelodysplastic Syndrome With Isolated Del(5q) / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes1
3CompletedTreatmentAdult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Promyelocytic Leukemia (M3) / Childhood Acute Promyelocytic Leukemia (M3) / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3CompletedTreatmentAnkylosing Spondylitis (AS)1
3CompletedTreatmentArthritis / Autoimmune Diseases / Rheumatoid Arthritis1
3CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
3CompletedTreatmentBladder Cancers / Urethral Cancer1
3CompletedTreatmentCancer, Breast17
3CompletedTreatmentCardiac Toxicity / Sarcomas1
3CompletedTreatmentCervical Cancers1
3CompletedTreatmentChildhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Anemia With Ringed Sideroblasts / Secondary Myelodysplastic Syndromes / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3CompletedTreatmentChildhood Acute Lymphoblastic Leukemia in Remission / Recurrent Childhood Acute Lymphoblastic Leukemia1
3CompletedTreatmentCrohn's Disease (CD)1
3CompletedTreatmentDermatomyositis / Polymyositis1
3CompletedTreatmentEarly Rheumatoid Arthritis2
3CompletedTreatmentEarly Stage Breast Cancer1
3CompletedTreatmentEarly-Stage Breast Cancer1
3CompletedTreatmentGood Prognosis Metastatic Gestational Trophoblastic Tumor / Hydatidiform Mole / Non-Metastatic Gestational Trophoblastic Tumor / Uterine Corpus Choriocarcinoma1
3CompletedTreatmentHead and Neck Cancers2
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentHydatidiform Mole1
3CompletedTreatmentJuvenile Idiopathic Arthritis (JIA)1
3CompletedTreatmentLeukemia, Lymphocytic, Acute / Leukemia, Myelocytic, Acute / Leukemia,Myeloid, Chronic / Myelodysplastic Syndromes1
3CompletedTreatmentLeukemia, Myelocytic, Acute2
3CompletedTreatmentLeukemias16
3CompletedTreatmentLeukemias / Lymphoma NOS4
3CompletedTreatmentLeukemias / Myelodysplastic Syndromes2
3CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
3CompletedTreatmentLiver Cirrhosis, Biliary3
3CompletedTreatmentLocalised High Grade Osteosarcoma of the Limbs / Osteosarcomas1
3CompletedTreatmentLymphoma NOS5
3CompletedTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentMacular Edema (ME) / Multiple Sclerosis (MS) / Uveitis, Intermediate1
3CompletedTreatmentNeoplasms, Breast1
3CompletedTreatmentPlaque Psoriasis1
3CompletedTreatmentPregnancy, Ectopic1
3CompletedTreatmentPsoriasis5
3CompletedTreatmentPsoriatic Arthritis1
3CompletedTreatmentRheumatoid Arthritis60
3CompletedTreatmentSeronegative Spondyloarthropathies1
3CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
3CompletedTreatmentStage III Bladder Cancer / Stage IV Bladder Cancer / Transitional Cell Carcinoma of the Bladder1
3CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
3CompletedTreatmentUntreated Childhood Medulloblastoma / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
3CompletedTreatmentUveitis1
3CompletedTreatmentModerate, refractory Atopic dermatitis1
3Not Yet RecruitingTreatmentAcute Lymphoblastic Leukemia, Pediatric1
3Not Yet RecruitingTreatmentB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Not Yet RecruitingTreatmentGestational Trophoblastic Neoplasms1
3Not Yet RecruitingTreatmentGraft Versus Host Disease (GVHD)1
3Not Yet RecruitingTreatmentLow Dose Methotrexate in Severe Chronic Asthma1
3Not Yet RecruitingTreatmentRheumatoid Arthritis1
3RecruitingNot AvailableRheumatoid Arthritis1
3RecruitingPreventionAcute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome1
3RecruitingPreventionDiffuse Large B-Cell Lymphoma (DLBCL)1
3RecruitingPreventionLeukaemia, Acute / Myelodysplasia1
3RecruitingSupportive CareAcute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Hodgkins Disease (HD) / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Non-Hodgkin's Lymphoma (NHL)1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
3RecruitingTreatmentAcute Promyelocytic Leukemia (APL)1
3RecruitingTreatmentAdult B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative / Untreated Adult Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAdult B Lymphoblastic Lymphoma / Childhood B Acute Lymphoblastic Leukemia / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Lymphoblastic Lymphoma / Down Syndrome (DS) / Stage I B Lymphoblastic Lymphoma / Stage II B Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAdult T Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAlopecia Areata (AA)1
3RecruitingTreatmentAtherosclerotic Cardiovascular Diseases / Vascular Inflammation1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / Bone Necrosis / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Pain / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia2
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentB-cell Non Hodgkin's Lymphoma / Mature B-cell Leukemia Burkitt-type1
3RecruitingTreatmentCardiovascular Diseases1
3RecruitingTreatmentChoriocarcinoma / FIGO Stage I Gestational Trophoblastic Tumor / FIGO Stage II Gestational Trophoblastic Tumor / FIGO Stage III Gestational Trophoblastic Tumor / Hydatidiform Mole1
3RecruitingTreatmentExtranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type1
3RecruitingTreatmentExtranodal NK/T-cell Lymphoma, Nasal Type1
3RecruitingTreatmentHead Neck Cancer Squamous Cell Recurrent1
3RecruitingTreatmentJuvenile Idiopathic Arthritis (JIA)1
3RecruitingTreatmentNeoplasms, Head and Neck1
3RecruitingTreatmentOsteosarcomas1
3RecruitingTreatmentPediatric Crohn's Disease1
3RecruitingTreatmentPersistent Pregnancy of Unknown Location / Pregnancy, Ectopic1
3RecruitingTreatmentPhiladelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia1
3RecruitingTreatmentPrimary Central Nervous System Lymphoma (PCNSL) / Primary CNS Lymphoma1
3RecruitingTreatmentPsoriatic Arthritis2
3RecruitingTreatmentRheumatoid Arthritis9
3RecruitingTreatmentTakayasu's Arteritis1
3RecruitingTreatmentUveitis1
3SuspendedTreatmentBrain Cancer / Choroid Plexus Tumors1
3SuspendedTreatmentCancer, Breast1
3TerminatedPreventionAcute Lymphoid Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Myeloid Leukemia (CML) / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome / Myeloproliferative Diseases1
3TerminatedSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS1
3TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3TerminatedTreatmentCancer, Breast1
3TerminatedTreatmentHearing Loss, Sensorineural1
3TerminatedTreatmentJuvenile Idiopathic Arthritis (JIA)1
3TerminatedTreatmentLeukemias1
3TerminatedTreatmentLymphoma NOS1
3TerminatedTreatmentPsoriasis1
3TerminatedTreatmentRheumatoid Arthritis4
3TerminatedTreatmentSarcomas1
3Unknown StatusTreatmentBladder Cancers1
3Unknown StatusTreatmentBrain and Central Nervous System Tumors2
3Unknown StatusTreatmentCancer, Breast2
3Unknown StatusTreatmentChronic Periaortitis / Idiopathic Retroperitoneal Fibrosis / Perianeurysmal Retroperitoneal Fibrosis1
3Unknown StatusTreatmentChronic Urticaria1
3Unknown StatusTreatmentJuvenile Dermatomyositis1
3Unknown StatusTreatmentLeukemias3
3Unknown StatusTreatmentLeukemias / Lymphoma NOS1
3Unknown StatusTreatmentLeukemias / Mucositis / Oral Complications1
3Unknown StatusTreatmentLymphoblastic Leukemia, Acute1
3Unknown StatusTreatmentLymphoma NOS4
3Unknown StatusTreatmentNonneoplastic Condition1
3Unknown StatusTreatmentPolyarthritis1
3Unknown StatusTreatmentRheumatoid Arthritis1
3WithdrawnTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS1
3WithdrawnTreatmentLeukemias1
4Active Not RecruitingBasic SciencePsoriasis1
4Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4Active Not RecruitingTreatmentRheumatoid Arthritis3
4CompletedNot AvailableMultiple Sclerosis, Relapsing-Remitting1
4CompletedNot AvailablePsoriatic Arthritis1
4CompletedNot AvailableRheumatoid Arthritis1
4CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)4
4CompletedTreatmentAdult Acute Lymphocytic Leukemia4
4CompletedTreatmentAnkylosing Spondylitis (AS)2
4CompletedTreatmentArthritis, Juvenile Rheumatoid / Juvenile Chronic Polyarthritis / Juvenile Idiopathic Arthritis (JIA)1
4CompletedTreatmentBurkitt's Leukemia / Burkitt's Lymphoma / Large Cell Anaplastic Lymphoma / Lymphoma, Lymphoblastic / Mediastinal Neoplasms1
4CompletedTreatmentCentral Nervous System Lymphoma1
4CompletedTreatmentCrohn's Disease (CD)1
4CompletedTreatmentGlycogen Storage Disease Type II / Pompe's Disease1
4CompletedTreatmentGraft Versus Host Disease (GVHD)1
4CompletedTreatmentLymphoma, Lymphoblastic1
4CompletedTreatmentMultiple Sclerosis (MS)1
4CompletedTreatmentPregnancy, Ectopic2
4CompletedTreatmentPsoriasis4
4CompletedTreatmentPsoriasis / Psoriatic Arthritis1
4CompletedTreatmentRheumatoid Arthritis30
4CompletedTreatmentUnwanted Pregnancies1
4CompletedTreatmentUveitis1
4Enrolling by InvitationBasic ScienceRheumatoid Arthritis1
4Enrolling by InvitationTreatmentChildhood Acute Promyelocytic Leukemia1
4Enrolling by InvitationTreatmentUlcerative Colitis (UC)1
4Not Yet RecruitingTreatmentCrohn's Disease (CD)2
4Not Yet RecruitingTreatmentInsufficient Response to Methotrexate / Rheumatoid Arthritis1
4Not Yet RecruitingTreatmentMeningeal Carcinomatosis1
4Not Yet RecruitingTreatmentPh+ Acute Lymphoblastic Leukemia1
4RecruitingBasic ScienceRheumatoid Arthritis1
4RecruitingPreventionBeta-Thalassemia Major1
4RecruitingPreventionAGVHD1
4RecruitingTreatmentALK-negative Anaplastic Large Cell Lymphoma / Angioimmunoblastic T Cell Lymphoma / Enteropathy Associated T Cell Lymphoma / Hepatosplenic T Cell Lymphoma / Peripherial T Cell Lymphoma,Not Otherwise Specified / Subcutaneous Panniculitis Like T Cell Lymphoma1
4RecruitingTreatmentAPL1
4RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)4
4RecruitingTreatmentCrohn's Disease (CD)2
4RecruitingTreatmentGlycogen Storage Disease Type II (GSD-II) / Glycogenesis 2 Acid Maltase Deficiency / Pompe's Disease1
4RecruitingTreatmentLymphoma, T-Cell, Cutaneous / Mycosis Fungoides (MF)1
4RecruitingTreatmentOphthalmopathy, Thyroid-Associated1
4RecruitingTreatmentPompe's Disease1
4RecruitingTreatmentPsoriasis1
4RecruitingTreatmentPsoriatic Arthritis1
4RecruitingTreatmentRheumatoid Arthritis6
4TerminatedTreatmentMacular Edema (ME) / Ocular Sarcoidosis / Sarcoid-associated Uveitis1
4TerminatedTreatmentModerate to Severe Rheumatoid Arthritis1
4TerminatedTreatmentRheumatoid Arthritis5
4Unknown StatusPreventionRheumatoid Arthritis1
4Unknown StatusTreatmentAdult Acute Lymphocytic Leukemia2
4Unknown StatusTreatmentArthritis / Rheumatoid Arthritis2
4Unknown StatusTreatmentPregnancy, Ectopic1
4Unknown StatusTreatmentRheumatoid Arthritis2
4Unknown StatusTreatmentSevere Plaque Type Psoriasis1
4WithdrawnTreatmentAnkylosing Spondylitis (AS) / Spondylarthropathy1
4WithdrawnTreatmentDemyelinating Disorders / Multiple Sclerosis (MS) / Myelitis / Neuritis / Optic Neuritis1
4WithdrawnTreatmentRheumatoid Arthritis2
Not AvailableActive Not RecruitingNot AvailableJIA / Juvenile Idiopathic Arthritis (JIA)1
Not AvailableActive Not RecruitingNot AvailableInflammatory processes / Psoriasis1
Not AvailableActive Not RecruitingTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableActive Not RecruitingTreatmentDiffuse Large B Cell Lymphoma (DLBCL) / Post Transplant Lymphoproliferative Disorder / Primary Mediastinal (Thymic) Large B-cell Lymphoma1
Not AvailableActive Not RecruitingTreatmentEarly Chikungunya Arthritis1
Not AvailableActive Not RecruitingTreatmentLeukemias1
Not AvailableActive Not RecruitingTreatmentLymphoma NOS1
Not AvailableCompletedNot AvailableAnkylosing Spondylitis (AS) / Psoriatic Arthritis / Rheumatoid Arthritis1
Not AvailableCompletedNot AvailableArthritis / High Dose / Rheumatoid1
Not AvailableCompletedNot AvailableDermatomyositis / Polymyositis1
Not AvailableCompletedNot AvailableEarly Diffuse Cutaneous Systemic Sclerosis1
Not AvailableCompletedNot AvailableInflammatory Bowel Diseases (IBD) / Psoriasis1
Not AvailableCompletedNot AvailableJuvenile Idiopathic Arthritis (JIA)1
Not AvailableCompletedNot AvailableLeukemias / Renal Toxicity1
Not AvailableCompletedNot AvailableMethotrexate Adverse Reaction1
Not AvailableCompletedNot AvailableOsteosarcomas1
Not AvailableCompletedNot AvailableOsteosarcomas / Spindle Cell Sarcoma of Bone1
Not AvailableCompletedNot AvailablePsoriasis1
Not AvailableCompletedNot AvailableRheumatoid Arthritis2
Not AvailableCompletedBasic ScienceRheumatoid Arthritis1
Not AvailableCompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
Not AvailableCompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T-Cell Leukemia/Lymphoma / Burkitt's Lymphoma / Lymphoid Malignancies (New or Relapsed) / Lymphoma, Lymphoblastic / Mantle Cell Lymphoma (MCL)1
Not AvailableCompletedTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Myelodysplastic Syndrome With Isolated Del(5q) / Polycythemia Vera (PV) / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Secondary Myelofibrosis / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
Not AvailableCompletedTreatmentAtaxia-Telangiectasia1
Not AvailableCompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableCompletedTreatmentBrain and Central Nervous System Tumors2
Not AvailableCompletedTreatmentBrain and Central Nervous System Tumors / Lymphoma NOS1
Not AvailableCompletedTreatmentCancer, Breast2
Not AvailableCompletedTreatmentChildhood Acute Lymphoblastic Leukemia in Remission1
Not AvailableCompletedTreatmentChildhood Langerhans Cell Histiocytosis1
Not AvailableCompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
Not AvailableCompletedTreatmentFasciitis1
Not AvailableCompletedTreatmentGraft Versus Host Disease (GVHD) / Mucositis1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableCompletedTreatmentInfertilities / Pregnancy, Ectopic1
Not AvailableCompletedTreatmentInflammatory Bowel Diseases (IBD)1
Not AvailableCompletedTreatmentL1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / Non-T, Non-B Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
Not AvailableCompletedTreatmentLeukemia, Lymphocytic, Acute1
Not AvailableCompletedTreatmentLeukemias2
Not AvailableCompletedTreatmentLeukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Nonmalignant Neoplasm / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableCompletedTreatmentLymphoma NOS1
Not AvailableCompletedTreatmentLymphoma, Large Cell / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableCompletedTreatmentLymphoma, Lymphoblastic1
Not AvailableCompletedTreatmentRheumatoid Arthritis3
Not AvailableCompletedTreatmentSarcomas1
Not AvailableCompletedTreatmentT-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableCompletedTreatmentType 1 Diabetes Mellitus (T1DM)1
Not AvailableCompletedTreatmentSynovitis of osteoarthritis1
Not AvailableNot Yet RecruitingTreatmentChronic Myeloid Leukemia (CML) / Leukaemia, Acute / Myelodysplastic Syndrome1
Not AvailableNot Yet RecruitingTreatmentRheumatoid Arthritis1
Not AvailableRecruitingNot AvailableBullous Pemphigoid (BP)1
Not AvailableRecruitingNot AvailablePsoriasis1
Not AvailableRecruitingNot AvailableRheumatoid Arthritis1
Not AvailableRecruitingNot AvailableSevere Aplastic Anemia (SAA)1
Not AvailableRecruitingTreatmentAcute Leukemias of Ambiguous Lineage / Childhood B Acute Lymphoblastic Leukemia / Mixed Phenotype Acute Leukemia (MPAL)1
Not AvailableRecruitingTreatmentAcute Lymphoblastic Leukemia Ph Positive1
Not AvailableRecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia1
Not AvailableRecruitingTreatmentCancers1
Not AvailableRecruitingTreatmentCrohn's Disease (CD) / Inflammatory Bowel Diseases (IBD) / Ulcerative Colitis (UC)1
Not AvailableRecruitingTreatmentFlu caused by Influenza / Methotrexate / Rheumatoid Arthritis1
Not AvailableRecruitingTreatmentPsoriatic Arthritis1
Not AvailableRecruitingTreatmentRecurrence (Disease Attribute)1
Not AvailableTerminatedTreatmentChediak-Higashi Syndrome / Chronic Granulomatous Disease (CGD) / Common Variable Immunodeficiency / Familial Erythrophagocytic Lymphohistiocytosis / Graft Versus Host Disease (GVHD) / Immunologic Deficiency Syndromes / Leukocyte Adhesion Deficiency Syndrome / Lymphohistiocytosis, Hemophagocytic / Severe Combined Immunodeficiency / Virus-Associated Hemophagocytic Syndrome / Wiskott-Aldrich Syndrome (WAS) / X-Linked Agammaglobulinemia / X-Linked Hyper IgM Syndrome / X-Linked Lymphoproliferative Syndrome1
Not AvailableTerminatedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Sarcomas1
Not AvailableTerminatedTreatmentDiabetic Macular Edema (DME)1
Not AvailableTerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableTerminatedTreatmentLeukemias / Lymphoma NOS1
Not AvailableTerminatedTreatmentOsteosarcomas1
Not AvailableTerminatedTreatmentT-Cell Lymphomas1
Not AvailableUnknown StatusNot AvailableCancer, Breast1
Not AvailableUnknown StatusNot AvailableJuvenile Idiopathic Arthritis (JIA)1
Not AvailableUnknown StatusNot AvailableScleritis / Uveitis1
Not AvailableUnknown StatusPreventionGraft Versus Host Disease (GVHD) / Hematopoietic Stem Cell Transplantation (HSCT)1
Not AvailableUnknown StatusTreatmentBehcet's Syndrome / Uveal Disease1
Not AvailableUnknown StatusTreatmentChediak-Higashi Syndrome / Familial Erythrophagocytic Lymphohistiocytosis / Graft Versus Host Disease (GVHD) / Lymphohistiocytosis, Hemophagocytic / Virus-Associated Hemophagocytic Syndrome / X-Linked Lymphoproliferative Syndrome1
Not AvailableUnknown StatusTreatmentChronic Myeloproliferative Disorders / Kidney Cancer / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
Not AvailableUnknown StatusTreatmentLeukemias2
Not AvailableUnknown StatusTreatmentLymphoma NOS1
Not AvailableUnknown StatusTreatmentOsteosarcomas1
Not AvailableUnknown StatusTreatmentPersistent Pregnancy of Unknown Location / Pregnancy, Ectopic1
Not AvailableUnknown StatusTreatmentRheumatoid Arthritis1
Not AvailableWithdrawnTreatmentLeptomeningeal Metastases1
Not AvailableWithdrawnTreatmentLymphoma NOS1
Pharmacoeconomics
Manufacturers
  • Abic ltd
  • Pharmacia and upjohn co
  • Hospira inc
  • App pharmaceuticals llc
  • Abraxis pharmaceutical products
  • Bedford laboratories div ben venue laboratories inc
  • Norbrook laboratories ltd
  • Pharmachemie usa inc
  • Bioniche pharma usa llc
  • Ebewe pharma ges mbh nfg kg
  • Pharmachemie bv
  • Bristol laboratories inc div bristol myers co
  • Bristol myers co
  • Bristol myers squibb
  • Barr laboratories inc
  • Dava pharmaceuticals inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Mylan pharmaceuticals inc
  • Roxane laboratories inc
Packagers
Dosage forms
FormRouteStrength
InjectionIntra-arterial; Intramuscular; Intrathecal; Intravenous25 mg/mL
Injection, powder, lyophilized, for solutionIntra-arterial; Intramuscular; Intrathecal; Intravenous1 g/1
Injection, solutionIntra-arterial; Intramuscular; Intrathecal; Intravenous1 g/40mL
Injection, solutionIntra-arterial; Intramuscular; Intravenous25 mg/mL
TabletOral2.5 mg
TabletOral2.5 mg/1
LiquidIntravenous10 mg
LiquidIntravenous2.5 mg
LiquidIntravenous25 mg
SolutionIntra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular10 mg
SolutionIntravenous25 mg
SolutionIntra-arterial; Intramuscular; Intrathecal; Intravenous10 mg
SolutionIntra-arterial; Intramuscular; Intrathecal; Intravenous15 mg
SolutionIntra-arterial; Intramuscular; Intrathecal; Intravenous20 mg
SolutionIntra-arterial; Intramuscular; Intrathecal; Intravenous7.5 mg
Injection, solutionIntra-arterial; Intramuscular; Intrathecal; Intravenous25 mg/mL
Powder, for solutionIntramuscular; Intrathecal; Intravenous20 mg
LiquidIntramuscular; Intrathecal; Intravenous25 mg
LiquidIntramuscular; Intrathecal; Intravenous50 mg
LiquidIntra-arterial; Intramuscular; Intrathecal; Intravenous25 mg
SolutionIntra-arterial; Intramuscular; Intrathecal; Intravenous25 mg
SolutionIntra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular25 mg
TabletOral10 mg
Powder, for solutionIntra-arterial; Intramuscular; Intrathecal; Intravenous20 mg
SolutionIntra-arterial; Intramuscular; Intravenous10 mg
SolutionIntra-arterial; Intramuscular; Intravenous15 mg
SolutionIntra-arterial; Intramuscular; Intravenous20 mg
SolutionIntra-arterial; Intramuscular; Intravenous25 mg
SolutionIntra-arterial; Intramuscular; Intravenous7.5 mg
SolutionSubcutaneous10 mg
SolutionSubcutaneous12.5 mg
SolutionSubcutaneous15 mg
SolutionSubcutaneous17.5 mg
SolutionSubcutaneous20 mg
SolutionSubcutaneous22.5 mg
SolutionSubcutaneous25 mg
SolutionSubcutaneous7.5 mg
Injection, solutionSubcutaneous10 mg
Injection, solutionSubcutaneous12.5 mg
Injection, solutionSubcutaneous15 mg
Injection, solutionSubcutaneous17.5 mg
Injection, solutionSubcutaneous20 mg
Injection, solutionSubcutaneous22.5 mg
Injection, solutionSubcutaneous25 mg
Injection, solutionSubcutaneous7.5 mg
Injection, solutionSubcutaneous10 mg/.4mL
Injection, solutionSubcutaneous12.5 mg/.4mL
Injection, solutionSubcutaneous15 mg/.4mL
Injection, solutionSubcutaneous17.5 mg/.4mL
Injection, solutionSubcutaneous22.5 mg/.4mL
Injection, solutionSubcutaneous25 mg/.4mL
Injection, solutionSubcutaneous7.5 mg/.4mL
Injection, solutionSubcutaneous10 mg/.2mL
Injection, solutionSubcutaneous12.5 mg/.25mL
Injection, solutionSubcutaneous15 mg/.3mL
Injection, solutionSubcutaneous17.5 mg/.35mL
Injection, solutionSubcutaneous20 mg/.4mL
Injection, solutionSubcutaneous22.5 mg/.45mL
Injection, solutionSubcutaneous25 mg/.5mL
Injection, solutionSubcutaneous27.5 mg/.55mL
Injection, solutionSubcutaneous30 mg/.6mL
Injection, solutionSubcutaneous7.5 mg/.15mL
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral15 mg/1
Tablet, film coatedOral5 mg/1
Tablet, film coatedOral7.5 mg/1
Prices
Unit descriptionCostUnit
Methotrexate powder261.33USD g
Rheumatrex 8 2.5 mg tablet Disp Pack169.98USD disp
Rheumatrex 24 2.5 mg tablet Disp Pack129.06USD disp
Rheumatrex 20 2.5 mg tablet Disp Pack107.59USD disp
Rheumatrex 12 2.5 mg tablet Disp Pack63.65USD disp
Methotrexate Sodium 25 mg/ml (pf) Solution 40ml Vial58.99USD vial
Trexall 15 mg tablet25.98USD tablet
Methotrexate Sodium 25 mg/ml (pf) Solution 10ml Vial24.99USD vial
Trexall 10 mg tablet17.67USD tablet
Methotrexate Sodium 25 mg/ml Solution 1 Vial = 2ml15.11USD vial
Methotrexate Sodium 25 mg/ml (pf) Solution 2ml Vial14.99USD vial
Trexall 7.5 mg tablet12.99USD tablet
Rheumatrex 2.5 mg tablet11.23USD tablet
Trexall 5 mg tablet8.66USD tablet
Methotrexate Sod. (Preserved) 25 mg/ml8.38USD ml
Methotrexate Sod.(Unpreserved) 25 mg/ml4.56USD ml
Methotrexate 2.5 mg tablet2.71USD tablet
Methotrexate 10 mg Tablet2.58USD tablet
Ratio-Methotrexate Sodium 2.5 mg Tablet0.66USD tablet
Apo-Methotrexate 2.5 mg Tablet0.66USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6746429 No2000-04-122020-04-12Us
US7744582 No1999-08-102019-08-10Us
US7776015 No1999-08-102019-08-10Us
US8021335 No2006-10-042026-10-04Us
US8480631 No2010-03-192030-03-19Us
US8562564 No2006-01-242026-01-24Us
US8579865 No2010-03-192030-03-19Us
US8664231 No2009-06-012029-06-01Us
US8945063 No2010-03-192030-03-19Us
USRE44846 No1999-08-102019-08-10Us
USRE44847 No1999-08-102019-08-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point195 °CNot Available
water solubility2600 mg/LNot Available
logP-1.85HANSCH,C ET AL. (1995)
Caco2 permeability-5.92ADME Research, USCD
pKa4.7SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.171 mg/mLALOGPS
logP-0.91ALOGPS
logP-0.5ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)3.41ChemAxon
pKa (Strongest Basic)2.81ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area210.54 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity119.21 m3·mol-1ChemAxon
Polarizability44.54 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8261
Blood Brain Barrier-0.9467
Caco-2 permeable-0.7754
P-glycoprotein substrateSubstrate0.8172
P-glycoprotein inhibitor INon-inhibitor0.7752
P-glycoprotein inhibitor IINon-inhibitor0.9879
Renal organic cation transporterNon-inhibitor0.8886
CYP450 2C9 substrateNon-substrate0.85
CYP450 2D6 substrateNon-substrate0.7968
CYP450 3A4 substrateSubstrate0.5177
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8333
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9739
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9517
BiodegradationNot ready biodegradable0.9741
Rat acute toxicity3.4955 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9564
hERG inhibition (predictor II)Non-inhibitor0.6958
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Download (10.1 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0fai-6900000000-25b0e287457fb3845ef4View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as glutamic acid and derivatives. These are compounds containing glutamic acid or a derivative thereof resulting from reaction of glutamic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganic acids and derivatives
Sub ClassCarboxylic acids and derivatives
Direct ParentGlutamic acid and derivatives
Alternative Parents
Substituents
  • Glutamic acid or derivatives
  • Hippuric acid or derivatives
  • Hippuric acid
  • N-acyl-alpha-amino acid
  • N-acyl-alpha amino acid or derivatives
  • Aminobenzamide
  • Aminobenzoic acid or derivatives
  • Pteridine
  • Benzamide
  • Benzoic acid or derivatives
  • Benzoyl
  • Aniline or substituted anilines
  • Dialkylarylamine
  • Tertiary aliphatic/aromatic amine
  • Aminopyrimidine
  • Aralkylamine
  • Monocyclic benzene moiety
  • Dicarboxylic acid or derivatives
  • Benzenoid
  • Primary aromatic amine
  • Pyrazine
  • Pyrimidine
  • Heteroaromatic compound
  • Secondary carboxylic acid amide
  • Tertiary amine
  • Amino acid
  • Carboxamide group
  • Organoheterocyclic compound
  • Azacycle
  • Carboxylic acid
  • Organooxygen compound
  • Organic nitrogen compound
  • Carbonyl group
  • Hydrocarbon derivative
  • Organic oxygen compound
  • Amine
  • Primary amine
  • Organopnictogen compound
  • Organonitrogen compound
  • Organic oxide
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Nadph binding
Specific Function:
Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. Binds its own mRNA and that of DHFRL1.
Gene Name:
DHFR
Uniprot ID:
P00374
Molecular Weight:
21452.61 Da
References
  1. Al-Rashood ST, Aboldahab IA, Nagi MN, Abouzeid LA, Abdel-Aziz AA, Abdel-Hamide SG, Youssef KM, Al-Obaid AM, El-Subbagh HI: Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs. Bioorg Med Chem. 2006 Dec 15;14(24):8608-21. Epub 2006 Sep 12. [PubMed:16971132 ]
  2. Assaraf YG: Molecular basis of antifolate resistance. Cancer Metastasis Rev. 2007 Mar;26(1):153-81. [PubMed:17333344 ]
  3. Bennett B, Langan P, Coates L, Mustyakimov M, Schoenborn B, Howell EE, Dealwis C: Neutron diffraction studies of Escherichia coli dihydrofolate reductase complexed with methotrexate. Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18493-8. Epub 2006 Nov 27. [PubMed:17130456 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Totani K, Matsuo I, Ihara Y, Ito Y: High-mannose-type glycan modifications of dihydrofolate reductase using glycan-methotrexate conjugates. Bioorg Med Chem. 2006 Aug 1;14(15):5220-9. Epub 2006 May 2. [PubMed:16647263 ]
  6. Uga H, Kuramori C, Ohta A, Tsuboi Y, Tanaka H, Hatakeyama M, Yamaguchi Y, Takahashi T, Kizaki M, Handa H: A new mechanism of methotrexate action revealed by target screening with affinity beads. Mol Pharmacol. 2006 Nov;70(5):1832-9. Epub 2006 Aug 25. [PubMed:16936229 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xanthine dehydrogenase activity
Specific Function:
Oxidase with broad substrate specificity, oxidizing aromatic azaheterocycles, such as N1-methylnicotinamide and N-methylphthalazinium, as well as aldehydes, such as benzaldehyde, retinal, pyridoxal, and vanillin. Plays a key role in the metabolism of xenobiotics and drugs containing aromatic azaheterocyclic substituents. Participates in the bioactivation of prodrugs such as famciclovir, catalyz...
Gene Name:
AOX1
Uniprot ID:
Q06278
Molecular Weight:
147916.735 Da
References
  1. Zientek M, Jiang Y, Youdim K, Obach RS: In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos. 2010 Aug;38(8):1322-7. doi: 10.1124/dmd.110.033555. Epub 2010 May 5. [PubMed:20444863 ]
  2. Baggott JE, Morgan SL: Methotrexate catabolism to 7-hydroxymethotrexate in rheumatoid arthritis alters drug efficacy and retention and is reduced by folic acid supplementation. Arthritis Rheum. 2009 Aug;60(8):2257-61. doi: 10.1002/art.24685. [PubMed:19644884 ]
  3. Jordan CG, Rashidi MR, Laljee H, Clarke SE, Brown JE, Beedham C: Aldehyde oxidase-catalysed oxidation of methotrexate in the liver of guinea-pig, rabbit and man. J Pharm Pharmacol. 1999 Apr;51(4):411-8. [PubMed:10385213 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein complex binding
Specific Function:
Catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for homocysteine remethylation to methionine.
Gene Name:
MTHFR
Uniprot ID:
P42898
Molecular Weight:
74595.895 Da
References
  1. Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4. Epub 2007 Jun 24. [PubMed:17586865 ]
  2. Kremer JM: Methotrexate pharmacogenomics. Ann Rheum Dis. 2006 Sep;65(9):1121-3. [PubMed:16905578 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Phosphogluconate dehydrogenase (decarboxylating) activity
Specific Function:
Catalyzes the oxidative decarboxylation of 6-phosphogluconate to ribulose 5-phosphate and CO(2), with concomitant reduction of NADP to NADPH.
Gene Name:
PGD
Uniprot ID:
P52209
Molecular Weight:
53139.56 Da
References
  1. Akkemik E, Budak H, Ciftci M: Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study. J Enzyme Inhib Med Chem. 2010 Aug;25(4):476-9. doi: 10.3109/14756360903257900. [PubMed:20235752 ]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Tetrahydrofolylpolyglutamate synthase activity
Specific Function:
Catalyzes conversion of folates to polyglutamate derivatives allowing concentration of folate compounds in the cell and the intracellular retention of these cofactors, which are important substrates for most of the folate-dependent enzymes that are involved in one-carbon transfer reactions involved in purine, pyrimidine and amino acid synthesis. Unsubstituted reduced folates are the preferred s...
Gene Name:
FPGS
Uniprot ID:
Q05932
Molecular Weight:
64608.53 Da
References
  1. Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4. Epub 2007 Jun 24. [PubMed:17586865 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Omega peptidase activity
Specific Function:
Hydrolyzes the polyglutamate sidechains of pteroylpolyglutamates. Progressively removes gamma-glutamyl residues from pteroylpoly-gamma-glutamate to yield pteroyl-alpha-glutamate (folic acid) and free glutamate. May play an important role in the bioavailability of dietary pteroylpolyglutamates and in the metabolism of pteroylpolyglutamates and antifolates.
Gene Name:
GGH
Uniprot ID:
Q92820
Molecular Weight:
35964.045 Da
References
  1. Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4. Epub 2007 Jun 24. [PubMed:17586865 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Nadph binding
Specific Function:
Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. Binds its own mRNA and that of DHFRL1.
Gene Name:
DHFR
Uniprot ID:
P00374
Molecular Weight:
21452.61 Da
References
  1. Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4. Epub 2007 Jun 24. [PubMed:17586865 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Thymidylate synthase activity
Specific Function:
Contributes to the de novo mitochondrial thymidylate biosynthesis pathway.
Gene Name:
TYMS
Uniprot ID:
P04818
Molecular Weight:
35715.65 Da
References
  1. Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4. Epub 2007 Jun 24. [PubMed:17586865 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Protein homodimerization activity
Specific Function:
Bifunctional enzyme that catalyzes 2 steps in purine biosynthesis.Promotes insulin receptor/INSR autophosphorylation and is involved in INSR internalization (PubMed:25687571).
Gene Name:
ATIC
Uniprot ID:
P31939
Molecular Weight:
64615.255 Da
References
  1. Hider SL, Bruce IN, Thomson W: The pharmacogenetics of methotrexate. Rheumatology (Oxford). 2007 Oct;46(10):1520-4. Epub 2007 Jun 24. [PubMed:17586865 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Warnecke A, Fichtner I, Sass G, Kratz F: Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B. Arch Pharm (Weinheim). 2007 Aug;340(8):389-95. [PubMed:17628030 ]
  2. Xie WJ, Feng YP, Cao SL, Zhao YF: [Study of the interaction between methotrexate and bovine serum albumin by spectrometry]. Guang Pu Xue Yu Guang Pu Fen Xi. 2006 Oct;26(10):1876-9. [PubMed:17205742 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).
Gene Name:
ABCC3
Uniprot ID:
O15438
Molecular Weight:
169341.14 Da
References
  1. Akita H, Suzuki H, Hirohashi T, Takikawa H, Sugiyama Y: Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3. Pharm Res. 2002 Jan;19(1):34-41. [PubMed:11837698 ]
  2. Oleschuk CJ, Deeley RG, Cole SP: Substitution of Trp1242 of TM17 alters substrate specificity of human multidrug resistance protein 3. Am J Physiol Gastrointest Liver Physiol. 2003 Feb;284(2):G280-9. Epub 2002 Oct 9. [PubMed:12388190 ]
  3. Hirohashi T, Suzuki H, Sugiyama Y: Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem. 1999 May 21;274(21):15181-5. [PubMed:10329726 ]
  4. Zeng H, Liu G, Rea PA, Kruh GD: Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res. 2000 Sep 1;60(17):4779-84. [PubMed:10987286 ]
  5. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. [PubMed:11585759 ]
  6. Paumi CM, Wright M, Townsend AJ, Morrow CS: Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry. 2003 May 13;42(18):5429-37. [PubMed:12731885 ]
  7. Li T, Ito K, Horie T: Transport of fluorescein methotrexate by multidrug resistance-associated protein 3 in IEC-6 cells. Am J Physiol Gastrointest Liver Physiol. 2003 Sep;285(3):G602-10. [PubMed:12909565 ]
  8. Zehnpfennig B, Urbatsch IL, Galla HJ: Functional reconstitution of human ABCC3 into proteoliposomes reveals a transport mechanism with positive cooperativity. Biochemistry. 2009 May 26;48(20):4423-30. doi: 10.1021/bi9001908. [PubMed:19334674 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. Chen ZS, Lee K, Kruh GD: Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem. 2001 Sep 7;276(36):33747-54. Epub 2001 Jul 10. [PubMed:11447229 ]
  2. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D: Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology. 2003 Aug;38(2):374-84. [PubMed:12883481 ]
  3. Bai J, Lai L, Yeo HC, Goh BC, Tan TM: Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol. 2004 Feb;36(2):247-57. [PubMed:14643890 ]
  4. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG: The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol. 2002 Mar;13(3):595-603. [PubMed:11856762 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Heijn M, Hooijberg JH, Scheffer GL, Szabo G, Westerhoff HV, Lankelma J: Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochim Biophys Acta. 1997 May 22;1326(1):12-22. [PubMed:9188796 ]
  2. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. [PubMed:11585759 ]
  3. Paumi CM, Wright M, Townsend AJ, Morrow CS: Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry. 2003 May 13;42(18):5429-37. [PubMed:12731885 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Lu R, Chan BS, Schuster VL: Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. Am J Physiol. 1999 Feb;276(2 Pt 2):F295-303. [PubMed:9950961 ]
  2. Kuze K, Graves P, Leahy A, Wilson P, Stuhlmann H, You G: Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells. J Biol Chem. 1999 Jan 15;274(3):1519-24. [PubMed:9880528 ]
  3. Uwai Y, Okuda M, Takami K, Hashimoto Y, Inui K: Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett. 1998 Nov 6;438(3):321-4. [PubMed:9827570 ]
  4. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
  5. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H: Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem. 1997 Jul 25;272(30):18526-9. [PubMed:9228014 ]
  6. Uwai Y, Iwamoto K: Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab Pharmacokinet. 2010;25(2):163-9. [PubMed:20460822 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name:
ABCC10
Uniprot ID:
Q5T3U5
Molecular Weight:
161627.375 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. [PubMed:14762099 ]
  2. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140 ]
  3. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713 ]
  4. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
  5. Uwai Y, Iwamoto K: Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab Pharmacokinet. 2010;25(2):163-9. [PubMed:20460822 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Han YH, Kato Y, Haramura M, Ohta M, Matsuoka H, Sugiyama Y: Physicochemical parameters responsible for the affinity of methotrexate analogs for rat canalicular multispecific organic anion transporter (cMOAT/MRP2). Pharm Res. 2001 May;18(5):579-86. [PubMed:11465411 ]
  2. Masuda M, I'izuka Y, Yamazaki M, Nishigaki R, Kato Y, Ni'inuma K, Suzuki H, Sugiyama Y: Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res. 1997 Aug 15;57(16):3506-10. [PubMed:9270020 ]
  3. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansen G: Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999 Jun 1;59(11):2532-5. [PubMed:10363967 ]
  4. Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol. 2000 Apr;57(4):760-8. [PubMed:10727523 ]
  5. Chen C, Scott D, Hanson E, Franco J, Berryman E, Volberg M, Liu X: Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats. Pharm Res. 2003 Jan;20(1):31-7. [PubMed:12608533 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Norris MD, De Graaf D, Haber M, Kavallaris M, Madafiglio J, Gilbert J, Kwan E, Stewart BW, Mechetner EB, Gudkov AV, Roninson IB: Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate. Int J Cancer. 1996 Mar 1;65(5):613-9. [PubMed:8598312 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Cattori V, van Montfoort JE, Stieger B, Landmann L, Meijer DK, Winterhalter KH, Meier PJ, Hagenbuch B: Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95. [PubMed:11713643 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Symporter activity
Specific Function:
Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate. Depending on the tissue and on cicumstances, mediates the import or export of lactic acid and ketone bod...
Gene Name:
SLC16A1
Uniprot ID:
P53985
Molecular Weight:
53943.685 Da
References
  1. Tamai I, Sai Y, Ono A, Kido Y, Yabuuchi H, Takanaga H, Satoh E, Ogihara T, Amano O, Izeki S, Tsuji A: Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1. J Pharm Pharmacol. 1999 Oct;51(10):1113-21. [PubMed:10579682 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Purine nucleotide transmembrane transporter activity
Specific Function:
Participates in physiological processes involving bile acids, conjugated steroids and cyclic nucleotides. Enhances the cellular extrusion of cAMP and cGMP. Stimulates the ATP-dependent uptake of a range of physiological and synthetic lipophilic anions, including the glutathione S-conjugates leukotriene C4 and dinitrophenyl S-glutathione, steroid sulfates such as dehydroepiandrosterone 3-sulfate...
Gene Name:
ABCC11
Uniprot ID:
Q96J66
Molecular Weight:
154299.625 Da
References
  1. Chen ZS, Guo Y, Belinsky MG, Kotova E, Kruh GD: Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol Pharmacol. 2005 Feb;67(2):545-57. Epub 2004 Nov 10. [PubMed:15537867 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, Adachi H, Fujiwara K, Okabe M, Suzuki T, Nunoki K, Sato E, Kakyo M, Nishio T, Sugita J, Asano N, Tanemoto M, Seki M, Date F, Ono K, Kondo Y, Shiiba K, Suzuki M, Ohtani H, Shimosegawa T, Iinuma K, Nagura H, Ito S, Matsuno S: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99. [PubMed:11375950 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Thyroid hormone transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent high affinity transport of organic anions such as the thyroid hormones thyroxine (T4) and rT3. Other potential substrates, such as triiodothyronine (T3), 17-beta-glucuronosyl estradiol, estrone-3-sulfate and sulfobromophthalein (BSP) are transported with much lower efficiency. May play a signifiant role in regulating T4 flux into and out of the brain (By similarity).
Gene Name:
SLCO1C1
Uniprot ID:
Q9NYB5
Molecular Weight:
78695.625 Da
References
  1. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ: Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002 Oct;16(10):2283-96. [PubMed:12351693 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as estrone-3-sulfate (PubMed:10873595). Mediates transport of prostaglandins (PG) E1 and E2, thyroxine (T4), deltorphin II, BQ-123 and vasopressin, but not DPDPE (a derivative of enkephalin lacking an N-terminal tyrosine residue), estrone-3-sulfate, taurocholate, digoxin nor DHEAS (PubMed:16971491).
Gene Name:
SLCO3A1
Uniprot ID:
Q9UIG8
Molecular Weight:
76552.135 Da
References
  1. Adachi H, Suzuki T, Abe M, Asano N, Mizutamari H, Tanemoto M, Nishio T, Onogawa T, Toyohara T, Kasai S, Satoh F, Suzuki M, Tokui T, Unno M, Shimosegawa T, Matsuno S, Ito S, Abe T: Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97. [PubMed:14631946 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y: ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9. Epub 2003 Apr 7. [PubMed:12682043 ]
  2. Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JH: Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004 Aug 15;64(16):5804-11. [PubMed:15313923 ]
  3. Mitomo H, Kato R, Ito A, Kasamatsu S, Ikegami Y, Kii I, Kudo A, Kobatake E, Sumino Y, Ishikawa T: A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem J. 2003 Aug 1;373(Pt 3):767-74. [PubMed:12741957 ]
  4. Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD: Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003 Jul 15;63(14):4048-54. [PubMed:12874005 ]
  5. Volk EL, Schneider E: Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43. [PubMed:14500392 ]
  6. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9. doi: 10.1111/j.1365-2125.2008.03303.x. Epub 2008 Nov 17. [PubMed:19076159 ]
  7. Hou YX, Li CZ, Palaniyandi K, Magtibay PM, Homolya L, Sarkadi B, Chang XB: Effects of putative catalytic base mutation E211Q on ABCG2-mediated methotrexate transport. Biochemistry. 2009 Sep 29;48(38):9122-31. doi: 10.1021/bi900675v. [PubMed:19691360 ]
  8. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. doi: 10.1016/j.bcp.2009.04.002. Epub 2009 Apr 11. [PubMed:19427995 ]
  9. Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW: Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett. 2009 Jun 28;279(1):74-83. doi: 10.1016/j.canlet.2009.01.027. Epub 2009 Feb 18. [PubMed:19232821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Sun W, Wu RR, van Poelje PD, Erion MD: Isolation of a family of organic anion transporters from human liver and kidney. Biochem Biophys Res Commun. 2001 May 4;283(2):417-22. [PubMed:11327718 ]
  2. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, Endou H: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82. [PubMed:9650585 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, Adachi H, Fujiwara K, Okabe M, Suzuki T, Nunoki K, Sato E, Kakyo M, Nishio T, Sugita J, Asano N, Tanemoto M, Seki M, Date F, Ono K, Kondo Y, Shiiba K, Suzuki M, Ohtani H, Shimosegawa T, Iinuma K, Nagura H, Ito S, Matsuno S: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99. [PubMed:11375950 ]
  2. van de Steeg E, van der Kruijssen CM, Wagenaar E, Burggraaff JE, Mesman E, Kenworthy KE, Schinkel AH: Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab Dispos. 2009 Feb;37(2):277-81. doi: 10.1124/dmd.108.024315. Epub 2008 Nov 20. [PubMed:19022939 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Methotrexate transporter activity
Specific Function:
Has been shown to act both as an intestinal proton-coupled high-affinity folate transporter and as an intestinal heme transporter which mediates heme uptake from the gut lumen into duodenal epithelial cells. The iron is then released from heme and may be transported into the bloodstream. Dietary heme iron is an important nutritional source of iron. Shows a higher affinity for folate than heme.
Gene Name:
SLC46A1
Uniprot ID:
Q96NT5
Molecular Weight:
49770.04 Da
References
  1. Nakai Y, Inoue K, Abe N, Hatakeyama M, Ohta KY, Otagiri M, Hayashi Y, Yuasa H: Functional characterization of human proton-coupled folate transporter/heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter. J Pharmacol Exp Ther. 2007 Aug;322(2):469-76. Epub 2007 May 2. [PubMed:17475902 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Organic anion transporter, capable of transporting pharmacological substances such as digoxin, ouabain, thyroxine, methotrexate and cAMP. May participate in the regulation of membrane transport of ouabain. Involved in the uptake of the dipeptidyl peptidase-4 inhibitor sitagliptin and hence may play a role in its transport into and out of renal proximal tubule cells. May be involved in the first...
Gene Name:
SLCO4C1
Uniprot ID:
Q6ZQN7
Molecular Weight:
78947.525 Da
References
  1. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui K, Ito S, Goto J, Abe T: Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74. Epub 2004 Mar 1. [PubMed:14993604 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Reduced folate carrier activity
Specific Function:
Transporter for the intake of folate. Uptake of folate in human placental choriocarcinoma cells occurs by a novel mechanism called potocytosis which functionally couples three components, namely the folate receptor, the folate transporter, and a V-type H(+)-pump.
Gene Name:
SLC19A1
Uniprot ID:
P41440
Molecular Weight:
64867.62 Da
References
  1. Qiu A, Jansen M, Sakaris A, Min SH, Chattopadhyay S, Tsai E, Sandoval C, Zhao R, Akabas MH, Goldman ID: Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell. 2006 Dec 1;127(5):917-28. [PubMed:17129779 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Receptor activity
Specific Function:
Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells. Has high affinity for folate and folic acid analogs at neutral pH. Exposure to slightly acidic pH after receptor endocytosis triggers a conformation change that strongly reduces its affinity for folates and mediates their release. Required for norma...
Gene Name:
FOLR1
Uniprot ID:
P15328
Molecular Weight:
29818.94 Da
References
  1. Sharma S, Das M, Kumar A, Marwaha V, Shankar S, Aneja R, Grover R, Arya V, Dhir V, Gupta R, Kumar U, Juyal RC, B K T: Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. Pharmacogenet Genomics. 2008 Dec;18(12):1041-9. [PubMed:19093297 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on April 26, 2017 04:14